The Journal of Clinical Psychiatry

Subject Index to Volume 65: January 2004 Through December 2004

Academic Highlights
Depression and Physical Symptoms: The Mind-Body Connection. June 867–876
Emerging Therapeutic Strategies in Alzheimer's Disease. Feb 255–266
Enhancing Treatment Response in Depression. Sept 1269–1280
Guidelines for the Use of Long-Acting Injectable Atypical Antipsychotics. Jan 120–131
International Consensus Group on Bipolar I Depression Treatment Guidelines. Apr 569–579
Sleepiness Versus Sleeplessness: Shift Work and Sleep Disorders. July 1007–1015
Utilizing Benzodiazepines in Clinical Practice: An Evidence-Based Discussion. Nov 1565–1574

Acetaminophen
Acetaminophen preferable to ibuprofen for pretreatment of electroconvulsive therapy–induced headache [letter]. Roth LS, May 726

Acne
Two cases of acneiform eruption associated with lamotrigine [letter]. Nielsen, Dec 1720–1722

Adjunctive Therapy see Drug Therapy, Combination

Adolescents
Atypical antipsychotics in the treatment of children and adolescents: clinical applications. Findling, Suppl 6, 30–44
Body mass index and future schizophrenia in Israeli male adolescents. Weiser, Nov 1546–1549
Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. Richardson, Jan 92–96
Cautionary note when using zonisamide in youths: a case report of association with toxic epidermal necrolysis [letter]. Majeres, Dec 1720
Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. State, Aug 1057–1063
Clinical characteristics of depressive symptoms in children and adolescents with major depressive disorder. Yorbik, Dec 1654–1659
Diagnosis and treatment of bipolar disorder in children and adolescents. Wagner, Suppl 15, 30–34
Diagnostic challenges in children and adolescents with psychotic disorders. Reimherr, Suppl 6, 5–11
Introduction: atypical antipsychotics in the treatment of children and adolescents. Findling, Suppl 6, 3–4
Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. Barbe, Jan 77–83
Naltrexone in the treatment of adolescent sexual offenders. Ryback, July 982–986
Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. Leon, July 915–918
Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. DelBello, Suppl 6, 12–19
Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. McConville, Suppl 6, 20–29

Adults
Clinical perspective of attention-deficit/hyperactivity disorder into adulthood. Wilens, Oct 1301–1313

Aggression
Higher levels of anger and aggressiveness in major depressive disorder than in anxiety and somatoform disorders [letter]. Picardi, Mar 442–443
Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. Nickel, Nov 1515–1519

Agitation
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Currier, Mar 386–394
Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? [letter] DeQuardo, Jan 132–133

Akathisia
Vitamin B_6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. Lerner, Nov 1550–1554

Alcohol
Alcohol use disorder comorbidity in eating disorders: a multicenter study. Bulik, July 1000–1006
Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. Wetzel, Oct 1406–1413
Use of propofol for alcohol withdrawal delirium: a case report [letter]. Takeshita, Jan 134–135

Algorithm
Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Miller, Apr 500–508

Alzheimer's Disease
Emerging Therapeutic Strategies in Alzheimer's Disease [Academic Highlights]. Feb 255–266

Amino Acid
Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. Richardson, Jan 92–96

Amisulpride
Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome [letter]. Atbasoglu, Dec 1724–1725
Transient hyperproinsulinemia during treatment with clozapine and amisulpride [letter]. Rettenbacher, June 878–879

Anger
Anger attacks in bipolar depression: predictors and response to citalopram added to mood stabilizers. Mammen, May 627–633
Anger in depressive mixed states [letter]. Benazzi; Mammen reply, Nov 1578–1579
Higher levels of anger and aggressiveness in major depressive disorder than in anxiety and somatoform disorders [letter]. Picardi, Mar 442–443

Anorexia Nervosa
Open trial of olanzapine in anorexia nervosa. Barbarich, Nov 1480–1482

Antibiotics
Respiratory infections rather than antibiotics may increase clozapine levels: a critical review of the literature [letter]. de Leon, Aug 1144–1145

Anticonvulsants
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as $\alpha_2\delta$ ligands at voltage-gated calcium channels [Brainstorms]. Stahl, May 596–597
Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA [Brainstorms]. Stahl, Mar 291–292
Anticonvulsants as anxiolytics, part 2: pregabalin and gabapentin as $\alpha_2\delta$ ligands at voltage-gated calcium channels [Brainstorms]. Stahl, Apr 460–461
Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels [Brainstorms]. Stahl, June 738–739
Newer anticonvulsants in the treatment of bipolar disorder. Yatham, Suppl 10, 28–35
Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? [Brainstorms] Stahl, Feb 149–150

Antidepressants
Antidepressants and suicide risk in the United States, 1985–1999. Grunebaum, Nov 1456–1462
Antidepressant-withdrawal mania: a critical review and synthesis of the literature. Andrade, July 987–993

Are two antidepressant mechanisms better than one? issues in clinical trial design and analysis. Leon, Suppl 4, 31–36
Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. Berle, Sept 1228–1234
Debate and discussion: in the treatment of depression, does selectivity of action matter? Suppl 4, 60–62
Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. Lucki, Suppl 4, 11–24
Dual-Action Debate: Does Pharmacology Matter? Suppl 17, 1–33
Effects of newer antidepressants on low-density lipoprotein cholesterol levels [letter]. Le Mellédo; Nicholas reply, July 1017–1018
How antidepressants help depression: mechanisms of action and clinical response. Delgado, Suppl 4, 25–30
Introduction. Pharmacologic treatments of major depression: are two mechanisms really better than one? Schatzberg, Suppl 4, 3–4
Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. Hirschfeld, Suppl 4, 46–52
No deterioration of cognitive performance in an aggressive unilateral and bilateral antidepressant rTMS add-on trial. Hausmann, June 772–782
Open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. Schwartz TL, Sept 1223–1227
Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. Leon, July 915–918
Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. Pomerantz, Mar 395–404
Remission versus response: the new gold standard of antidepressant care. Keller, Suppl 4, 53–59
Selective versus multi-transmitter antidepressants: are two mechanisms better than one? Burke, Suppl 4, 37–45
Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. Owens, Suppl 4, 5–10
Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. Krell, Sept 1174–1179
Suicidality as a possible side effect of antidepressant treatment [commentary]. Culpepper, June 742–749
Treatment of postpartum depression, part 1: a critical review of biological interventions. Dennis, Sept 1242–1251

Antipsychotics

Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. Newcomer, Suppl 18, 36–46
Adherence to conventional and atypical antipsychotics after hospital discharge. Diaz, Mar 354–360
Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. Spoelstra, May 674–678
Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. Suppl 7, 1–20
Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. Freudenreich, Oct 1372–1376
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Lee E, June 864–866
Atypical antipsychotics in the treatment of children and adolescents: clinical applications. Findling, Suppl 6, 30–44
Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. Lawlor, Suppl 11, 5–10
Case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics [letter]. Toki, Nov 1576–1577
Clinicians' reasons for antipsychotic coprescribing. Sernyak, Dec 1597–1600
Consensus development conference on antipsychotic drugs and obesity and diabetes. Feb 267–272
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. Alméras, Apr 557–564
Diagnostic challenges in children and adolescents with psychotic disorders. Reimherr, Suppl 6, 5–11
Dyslipidemia and atypical antipsychotic drugs. Casey, Suppl 18, 27–35
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach, Mar 312–321
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. Lindenmayer, Apr 551–556
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. Yamashita, Nov 1525–1530
Efficacy of atypical antipsychotics in elderly patients with dementia. Tariot, Suppl 11, 11–15
Expert Consensus Guideline Series: Using Antipsychotic Agents in Older Patients, Suppl 2, 1–105
Guidelines for the Use of Long-Acting Injectable Atypical Antipsychotics [Academic Highlights]. Jan 120–131
Historical perspective on movement disorders. Friedman, Suppl 9, 3–8
Hyperlipidemia in persons using antipsychotic medication: a general population–based birth cohort study. Saari, Apr 547–550
Introduction: atypical antipsychotics in the treatment of children and adolescents. Findling, Suppl 6, 3–4
Introduction: clinical effectiveness of atypical antipsychotics in dementia. Tariot, Suppl 11, 3–4
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. Baskys, Suppl 11, 16–22
Managing atypical antipsychotic–associated weight gain: 12-month data on a multimodal weight control program. Menza, Apr 471–477
Metabolic effects of treatment with atypical antipsychotics [commentary]. Kane, Nov 1447–1455
Neuroleptic malignant syndrome and atypical antipsychotic drugs. Ananth, Apr 464–470
New nomenclature for drug-induced movement disorders including tardive dyskinesia. Chouinard, Suppl 9, 9–15
Pathophysiology of antipsychotic drug–induced movement disorders. Casey, Suppl 9, 25–28
Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. DelBello, Suppl 6, 12–19
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. Rachid, Nov 1537–1545
Possible role of divalproex sodium in sedation induced by antipsychotic medications [letter]. Berigan, Jan 133; Makela reply, Dec 1725
Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. Lamberti, May 702–706
Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. Montgomery, Nov 1491–1498
Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Ganguly, Oct 1377–1388
Prophylactic antipsychotics: do they keep you from catching schizophrenia? [Brainstorms] Stahl, Nov 1445–1446
Relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. Ballard, Suppl 11, 23–28
Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. Sevy, June 756–765
Schizophrenia and obesity: impact of antipsychotic medications. Wirshing, Suppl 18, 13–26
Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. Weinmann, Aug 1099–1105
Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. Kane, Suppl 9, 16–20
Tardive dyskinesia rates with atypical antipsychotics in older adults. Jeste, Suppl 9, 21–24
Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Miller, Apr 500–508
Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. McConville, Suppl 6, 20–29
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Aman, Sept 1197–1210

Antiretroviral Treatments

Use of newer antiretroviral treatments among HIV-infected Medicaid beneficiaries with serious mental illness. Walkup, Sept 1180–1189

Anxiety see also specific disorders

Cognitive-behavioral therapy for the treatment of anxiety disorders. Otto, Suppl 5, 34–41

Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert, Aug 1069–1075
Higher levels of anger and aggressiveness in major depressive disorder than in anxiety and somatoform disorders [letter]. Picardi, Mar 442–443
Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. Boylan, Aug 1106–1113
In the puerperium, primiparae exhibit higher levels of anxiety and serum peptidase activity and greater immune responses than multiparae. Maes, Jan 71–76
Introduction. Beyond refractory obsessions and anxiety states: toward remission. Hollander, Suppl 14, 3–5
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. Joliat, Mar 373–378
National trends in the outpatient treatment of anxiety disorders. Olfson, Sept 1166–1173
On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. Zimmerman, Oct 1400–1405
Qualitative review of SNRIs in anxiety. Silverstone, Suppl 17, 19–28
Remission rates in patients with anxiety disorders treated with paroxetine. Ballenger, Dec 1696–1707
Use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. Misri, Sept 1236–1241
What characteristics of primary anxiety disorders predict subsequent major depressive disorder? Bittner, May 618–626

Anxiolytics

Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA [Brainstorms]. Stahl, Mar 291–292

Apolipoprotein E

Lack of association between plasma apolipoprotein E and suicide attempts [letter]. Baca-Garcia, Apr 580–581

Aripiprazole

Comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. McQuade, Suppl 18, 47–56
Possible increased efficacy of low-dose clozapine when combined with aripiprazole [letter]. Lim, Sept 1284–1285
Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report [letter]. Anghelescu, Sept 1286–1287
Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? [letter] DeQuardo, Jan 132–133

Assessment

Computer-assisted self-assessment in persons with severe mental illness. Chinman, Oct 1343–1351

Attention-Deficit/Hyperactivity Disorder

ADHD treatment across the life cycle. Spencer, Suppl 3, 22–26
Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. Murphy, Suppl 3, 12–17
Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. State, Aug 1057–1063
Clinical perspective of attention-deficit/hyperactivity disorder into adulthood. Wilens, Oct 1301–1313
Clinical presentations of adult patients with ADHD. Adler, Suppl 3, 8–11
Diagnosing and Treating Attention-Deficit/Hyperactivity Disorder in Adults. Suppl 3, 1–48
Diagnosis and treatment of ADHD in adults in primary care. Montano, Suppl 3, 18–21
Guide to the treatment of adults with ADHD. Weiss MD, Suppl 3, 27–37
Impact of ADHD and its treatment on substance abuse in adults. Wilens, Suppl 3, 38–45
Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. Biederman, Suppl 3, 3–7
Prepubertal bipolar I disorder and bipolar disorder NOS are separable from ADHD [editorial]. Post, July 898–902

Augmentation see Drug Therapy, Combination

Autism

Effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. Cohen, Jan 110–113

Behavior Disorders

Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Aman, Sept 1197–1210

Benzodiazepines

Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. Clark, Feb 151–155
High-potency benzodiazepines: recent clinical results. Moroz, Suppl 5, 13–18
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. Chouinard, Suppl 5, 7–12
Prescribing benzodiazepines for patients with substance use disorders [letter]. Lieberman; Clark reply, Nov 1577–1578
Revisiting the Use of High-Potency Benzodiazepines. Suppl 5, 1–44
Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. Davidson, Suppl 5, 29–33
Utilizing Benzodiazepines in Clinical Practice: An Evidence-Based Discussion [Academic Highlights]. Nov 1565–1574

Bias

Potential for detection bias in the association between olanzapine and diabetes [letter]. Compton; Caro reply, Feb 274–275

Binge-Eating Disorder

Schizophrenia and binge-eating disorders [letter]. Ramacciotti, July 1016–1017
Topiramate in the long-term treatment of binge-eating disorder associated with obesity. McElroy, Nov 1463–1469
Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. McElroy, Jan 50–56

Bipolar Disorder

Anger attacks in bipolar depression: predictors and response to citalopram added to mood stabilizers. Mammen, May 627–633
Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? Kleindienst, July 966–974
Bipolar Care: Optimal Therapeutic Interventions Based on New Strategies. Suppl 15, 1–48
Bipolar patients with suicidal behavior: toward the identification of a clinical subgroup. Slama, Aug 1035–1039
Call to clinical action. Suppl 15, 4
Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. State, Aug 1057–1063
Clinical and legal correlates of inmates with bipolar disorder at time of criminal arrest. Quanbeck, Feb 198–203
Comparison of rapid-cycling and non–rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. Vieta, Oct 1420–1428
Correlates of suicidal behavior and lithium treatment in bipolar disorder. Dunner, Suppl 10, 5–10
Defining and improving response to treatment in patients with bipolar disorder. Keck, Suppl 15, 25–29
Diagnosing and treating comorbid (complicated) bipolar disorder. McElroy, Suppl 15, 35–44
Diagnosis and treatment of bipolar disorder in children and adolescents. Wagner, Suppl 15, 30–34
Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence? [Brainstorms] Stahl, Oct 1298–1299
Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. Khan, Nov 1483–1490
Employing pharmacologic treatment of bipolar disorder to greatest effect. Schatzberg, Suppl 15, 15–20
Evaluation and management of breakthrough depressive episodes. Keck, Suppl 10, 11–15
52-Week, open-label continuation study of lamotrigine in the treatment of bipolar depression. McElroy, Feb 204–210
Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. Gould, Jan 10–21
Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. Boylan, Aug 1106–1113
Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. Calabrese, Nov 1499–1504
Importance of subsyndromal symptoms in bipolar disorder. Marangell, Suppl 10, 24–27
Improving the course of illness and promoting continuation of treatment of bipolar disorder. Keller, Suppl 15, 10–14
International Consensus Group on Bipolar I Depression Treatment Guidelines [Academic Highlights]. Apr 569–579
Introduction: managing bipolar depression. Bowden, Suppl 10, 3–4
Introduction: new treatments for bipolar disorder. Suppl 15, 3

Making optimal use of combination pharmacotherapy in bipolar disorder. Bowden, Suppl 15, 21–24
Managing Bipolar Depression. Suppl 10, 1–38
Multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. Weisler, Apr 478–484
Newer anticonvulsants in the treatment of bipolar disorder. Yatham, Suppl 10, 28–35
Pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Goodwin, Mar 432–441
Prepubertal bipolar I disorder and bipolar disorder NOS are separable from ADHD [editorial]. Post, July 898–902
Psychosis in mania: specificity of its role in severity and treatment response. Swann AC, June 825–829
Recognition and diagnosis of bipolar disorder. Hirschfeld, Suppl 15, 5–9
Response to commentary: Using questionnaires to screen for psychiatric disorders [letter]. Hirschfeld, May 721–722
Risperidone and paroxetine given singly and in combination for bipolar depression. Shelton RC, Dec 1715–1719
Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. Bowden, May 707–714
Self-reported participation in nonpharmacologic treatments for bipolar disorder [letter]. Dennehy, Feb 278
6-Month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. Ketter, May 668–673
Strategies for preventing the recurrence of bipolar disorder. Ghaemi, Suppl 10, 16–23
Suicide attempts and ideation in patients with bipolar I disorder. Fagiolini, Apr 509–514
Using questionnaires to screen for psychiatric disorders: a comment on a study of screening for bipolar disorder in the community [commentary]. Zimmerman, May 605–610
Weight gain during treatment of bipolar I patients with olanzapine. Hennen, Dec 1679–1687

Body Image

Body-image dissatisfaction in gay versus heterosexual men: is there really a difference? Hausmann, Nov 1555–1558

Body Mass Index

Body mass index and future schizophrenia in Israeli male adolescents. Weiser, Nov 1546–1549

Bone

Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. Misra, Dec 1607–1618

Books Reviewed

Abrams DB, Niaura R, Brown RA, Emmons KM, Goldstein MG, Monti PM: *The Tobacco Dependence Treatment Handbook: A Guide to Best Practices*. Finlayson, May 727–728
Abrams R: *Electroconvulsive Therapy, 4th ed.* Dunner, Feb 280
Agronin ME. *Dementia: A Practical Guide*. Brown, June 884
American Psychiatric Association: *Quality Indicators: Defining and Measuring Quality in Psychiatric Care for Adults and Children (Report of the APA Task Force on Quality Indicators and Report of the APA Task Force on Quality Indicators for Children)*. Trevino JJ, Apr 585
Buchanan A (ed): *Care of the Mentally Disordered Offender in the Community*. Nizny, June 883–884
Cohen CI (ed): *Schizophrenia Into Later Life: Treatment, Research, and Policy*. Lee MA, May 729
Favazza A: *PsychoBible: Behavior, Religion and the Holy Book*. Freeman AM III, July 1022–1023
Gabbard GO: *Long-Term Psychodynamic Psychotherapy: A Basic Text*. Nash, July 1023
Geller B, DelBello MP (eds): *Bipolar Disorder in Childhood and Early Adolescence*. Mohmand, Aug 1151–1152
Ghaemi SN: *The Concepts of Psychiatry: A Pluralistic Approach to the Mind and Mental Issues*. Lomax, Oct 1435
Hay DP, Klein DT, Hay LK, Grossberg GT, Kennedy JS (eds): *Agitation in Patients With Dementia: A Practical Guide to Diagnosis and Management*. Palmer, Sept 1288
Holmes J, Bateman A (eds): *Integration in Psychotherapy: Models and Methods*. Perlmutter, May 728
Johnson B, Ruiz P, Galanter M (eds). *Handbook of Clinical Alcoholism Treatment*. Trevino, Dec 1726–1727
Kirshner HS: *Behavioral Neurology: Practical Science of Mind and Brain, 2nd ed*. Salomon, Mar 448
Kornstein SG, Clayton AH (eds): *Women's Mental Health: A Comprehensive Textbook*. Epstein, Mar 448–449
Leahy RL: *Cognitive Therapy Techniques: A Practitioner's Guide*. Chaitin, Nov 1581
Leo RJ: *Concise Guide to Pain Management for Psychiatrists*. Buffenstein A, Apr 585
Mann SC, Caroff SN, Keck PE Jr, Lazarus A: *Neuroleptic Malignant Syndrome and Related Conditions, 2nd ed*. Regan, May 728–729
McNally RJ: *Remembering Trauma*. Ford, Nov 1580
Mellow AM (ed): *Geriatric Psychiatry*. Salzman, Sept 1289
Miller MD, Reynolds CF: *Living Longer Depression Free: A Family Guide to Recognizing, Treating, and Preventing Depression in Later Life*. Thienhaus, Jan 137
Morrison J, Muñoz RA: *Boarding Time: The Psychiatry Candidate's New Guide to Part II of the ABPN Examination, 3rd ed*. Sudak, July 1022
Mueser KT, Noordsy DL, Drake RE, Fox L: *Integrated Treatment for Dual Disorders: A Guide to Effective Practice*. Weinstein, Dec 1727
Panksepp J: *Textbook of Biological Psychiatry*. Salomon, Aug 1152–1153
Pathé M: *Surviving Stalking*. Joseph, Mar 449
Potokar J, Thase ME (eds): *Advances in the Management and Treatment of Depression*. Dunner, May 729
Reite M, Ruddy J, Nagel K: *Concise Guide to Evaluation and Management of Sleep Disorders, 3rd ed*. Rack, Mar 449–450
Robinson DJ: *Reel Psychiatry: Movie Portrayals of Psychiatric Conditions*. Fitzgerald, Aug 1152
Shulman KI, Feinstein A: *Quick Cognitive Screening for Clinicians: Mini Mental, Clock Drawing, and Other Brief Tests*. Rabins, Nov 1581
Simon RI, Gold LH (eds): *The American Psychiatric Publishing Textbook of Forensic Psychiatry*. Montgomery, Nov 1580–1581
Spitzer RL, First MB, Gibbon M, Williams JBW (eds): *Treatment Companion to the DSM-IV-TR Casebook*. Andreasen, Oct 1435–1436
Stern TA, Herman JB: *Massachusetts General Hospital 1000 Psychiatry Questions & Annotated Answers*. Andreasen, Sept 1288–1289
Stern TA, Herman JB (eds): *Massachusetts General Hospital Psychiatry Update and Board Preparation, Second Edition*. Andreasen, Sept 1288–1289
Volavka J: *Neurobiology of Violence, Second Edition*. Feldmann, May 727
Westermeyer JJ, Weiss RD, Ziedonis DM (eds): *Integrated Treatment for Mood and Substance Use Disorder*. Ruiz, Aug 1151
Winston A: *Handbook of Integrated Short-Term Psychotherapy*. Schwab, Jan 136–137
Winston A, Rosenthal RN, Pinsker H (eds). *Introduction to Supportive Psychotherapy*. Nash, Dec 1726

Borderline Personality Disorder

Association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. Frankenburg, Dec 1660–1665
Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Philipsen, Oct 1414–1419
Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Simpson, Mar 379–385
Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. Gunderson, Aug 1049–1056
Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. Zanarini, Jan 28–36
Olanzapine versus placebo in the treatment of borderline personality disorder. Bogenschutz, Jan 104–109
Preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Zanarini, July 903–907
Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. Nickel, Nov 1515–1519
Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services [letter]. Pascual, Sept 1281–1283

Brain

Structural and functional brain changes in posttraumatic stress disorder. Nutt, Suppl 1, 11–17

Brain Stimulation
Psychiatric complications of deep brain stimulation for Parkinson's disease. Piasecki, June 845–849
Brainstorms
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as $\alpha_2\delta$ ligands at voltage-gated calcium channels. Stahl, May 596–597
Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA. Stahl, Mar 291–292
Anticonvulsants as anxiolytics, part 2: pregabalin and gabapentin as $\alpha_2\delta$ ligands at voltage-gated calcium channels. Stahl, Apr 460–461
Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. Stahl, June 738–739
Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence? Stahl, Oct 1298–1299
Mechanism of action of $\alpha_2\delta$ ligands: voltage sensitive calcium channel (VSCC) modulators. Stahl, Aug 1033–1034
Mechanism of action of voltage sensitive sodium channel modulators. Stahl, July 894–895
Preemptive analgesia: is pain less costly when you pre-pay for it? Stahl, Dec 1591–1592
Prophylactic antipsychotics: do they keep you from catching schizophrenia? Stahl, Nov 1445–1446
Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? Stahl, Feb 149–150
Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. Stahl, Sept 1162–1163
Symptoms and circuits, pt 3: schizophrenia. Stahl, Jan 8–9
Breast Cancer
Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. Grassi, Apr 515–520
Breastfeeding
Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. Berle, Sept 1228–1234
Bupropion and breastfeeding: a case of a possible infant seizure [letter]. Chaudron, June 881–882
Bright Light Therapy
Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. Epperson, Mar 421–425
Bupropion
Alternative pharmacotherapy for trichotillomania: a report of successful bupropion use [letter]. Bhanji, 1283
Bupropion and breastfeeding: a case of a possible infant seizure [letter]. Chaudron, June 881–882
Case report of mania related to discontinuation of bupropion therapy for smoking cessation [letter]. Michael, Feb 277
Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. Lam, Mar 337–340
Placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor–induced sexual dysfunction. Clayton, Jan 62–67
Rose by any other name [letter]. Sutor, 584
Cabergoline
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. Cavallaro, Feb 187–190
Calcium Channels
Mechanism of action of $\alpha_2\delta$ ligands: voltage sensitive calcium channel (VSCC) modulators [Brainstorms]. Stahl, Aug 1033–1034
Canada
Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Curkendall, May 715–720
Carbamazepine
Multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. Weisler, Apr 478–484
6-Month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. Ketter, May 668–673
Cardiovascular Health
Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. Suppl 7, 1–20
Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Curkendall, May 715–720
Childhood maltreatment as a risk factor for adult cardiovascular disease and depression. Batten, Feb 249–254
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. Alméras, Apr 557–564
Case Reports
Searching the medical literature for case reports [letter]. Mago; Gupta N reply, Mar 444–446
Catatonia
Catatonia is a risk factor for neuroleptic malignant syndrome [letter]. Carroll, Dec 1722–1723
Child Abuse
Childhood maltreatment as a risk factor for adult cardiovascular disease and depression. Batten, Feb 249–254
Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization. Arnow, Suppl 12, 10–15
Serotonin function, personality-trait variations, and childhood abuse in women with bulimia-spectrum eating disorders. Steiger, June 830–837
Children
Association of small life events with self reports of tic severity in pediatric and adult tic disorder patients: a prospective longitudinal study. Hoekstra, Mar 426–431
Atypical antipsychotics in the treatment of children and adolescents: clinical applications. Findling, Suppl 6, 30–44
Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. Richardson, Jan 92–96
Cautionary note when using zonisamide in youths: a case report of association with toxic epidermal necrolysis [letter]. Majeres, Dec 1720
Childhood maltreatment as a risk factor for adult cardiovascular disease and depression. Batten, Feb 249–254
Clinical characteristics of depressive symptoms in children and adolescents with major depressive disorder. Yorbik, Dec 1654–1659
Diagnosis and treatment of bipolar disorder in children and adolescents. Wagner, Suppl 15, 30–34
Diagnostic challenges in children and adolescents with psychotic disorders. Reimherr, Suppl 6, 5–11
Introduction: atypical antipsychotics in the treatment of children and adolescents. Findling, Suppl 6, 3–4
Neurobiological consequences of childhood trauma. Nemeroff, Suppl 1, 18–28
Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. Leon, July 915–918
Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. DelBello, Suppl 6, 12–19
Prepubertal bipolar I disorder and bipolar disorder NOS are separable from ADHD [editorial]. Post, July 898–902
Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization. Arnow, Suppl 12, 10–15
Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. McConville, Suppl 6, 20–29
China
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Lee E, June 864–866
Cholesterol
Effects of newer antidepressants on low-density lipoprotein cholesterol levels [letter]. Le Mellédo; Nicholas reply, July 1017–1018
Circadian Rhythm
Assessment of excessive sleepiness and insomnia as they relate to circadian rhythm sleep disorders. Doghramji K, Suppl 16, 17–22
Citalopram
Anger attacks in bipolar depression: predictors and response to citalopram added to mood stabilizers. Mammen, May 627–633
Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. Lam, Mar 337–340
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Pallanti, Oct 1394–1399
Clinical Trials
Are two antidepressant mechanisms better than one? issues in clinical trial design and analysis. Leon, Suppl 4, 31–36
Clonazepam
Development of clonazepam as a psychotropic: the Massachusetts General Hospital experience. Rosenbaum, Suppl 5, 3–6

Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Seedat, Feb 244–248

Clonidine

Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Philipsen, Oct 1414–1419

Clozapine

Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Lu M-L, June 766–771

Clozapine and hypertension: a chart review of 82 patients. Henderson, May 686–689

Effect of clozapine on factors controlling glucose homeostasis. Howes, Oct 1352–1355

Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. Glick, May 679–685

Possible increased efficacy of low-dose clozapine when combined with aripiprazole [letter]. Lim, Sept 1284–1285

Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Volavka J, Jan 57–61

Respiratory infections rather than antibiotics may increase clozapine levels: a critical review of the literature [letter]. de Leon, Aug 1144–1145

Transient hyperproinsulinemia during treatment with clozapine and amisulpride [letter]. Rettenbacher, June 878–879

Two-year follow-up of a patient with successful continuation of clozapine treatment despite morning pseudoneutropenia [letter]. Esposito, Sept 1281

Cocaine

Gabapentin reduces cocaine use among addicts from a community clinic sample. Raby, Jan 84–86

Cognition

Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Harvey, Mar 361–372

Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. Khan, Nov 1483–1490

Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? [letter] Duggal; Hofer reply, Aug 1145–1146

Cognitive-Behavioral Therapy

Cognitive-behavioral approaches to the treatment of insomnia. Morin, Suppl 16, 33–40

Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list–controlled open trial. Tolin, July 922–931

Cognitive-behavioral therapy for the treatment of anxiety disorders. Otto, Suppl 5, 34–41

Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. Wetzel, Oct 1406–1413

Treating generalized anxiety disorder with cognitive-behavioral therapy. Lang, Suppl 13, 14–19

Use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. Misri, Sept 1236–1241

Comorbidity

Diagnosing and treating comorbid (complicated) bipolar disorder. McElroy, Suppl 15, 35–44

Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. Diniz, Jan 22–27

Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. Boylan, Aug 1106–1113

Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. Biederman, Suppl 3, 3–7

Compliance see Medication Adherence

Computers

Computer-assisted self-assessment in persons with severe mental illness. Chinman, Oct 1343–1351

Consensus Statements

Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Harvey, Mar 361–372

Consensus development conference on antipsychotic drugs and obesity and diabetes. Feb 267–272

Consensus statement update on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 1, 55–62

Expert Consensus Guideline Series: Using Antipsychotic Agents in Older Patients, Suppl 2, 1–105

Update on Posttraumatic Stress Disorder. Suppl 1, 1–62

Consortium for Research in ECT

Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. Husain, Apr 485–491

Continuing Medical Education

Medical education: our mission and our success. Feb 147–148

Coping Behavior

Severe acute respiratory syndrome–related psychiatric and posttraumatic morbidities and coping responses in medical staff within a primary health care setting in Singapore. Sim, Aug 1120–1127

Corrections

Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Nasrallah, Apr 531–536; Correction, Aug 1150

Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Corya, 2003 Nov 1349–1356. Correction, Feb 279

Possible role of divalproex sodium in sedation induced by antipsychotic medications [letter]. Berigan, Jan 133; Correction, Dec 1725

Costs of Medical Care

Comments on cost analysis of risperidone versus olanzapine [letter]. Duggal; Taylor reply, June 879–880

Cost consequences of treatment-resistant depression. Russell, Mar 341–347

Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. Sevy, June 756–765

Criminology

Clinical and legal correlates of inmates with bipolar disorder at time of criminal arrest. Quanbeck, Feb 198–203

Cushing's Syndrome

Metyrapone for delirium due to Cushing's syndrome induced by occult ectopic adrenocorticotropic hormone secretion [letter]. Kawashima, July 1019–1020

Delirium

Risperidone in the treatment of delirium: results from a prospective open-label trial. Mittal, May 662–667

Risperidone in the treatment of patients with delirium. Parellada, Mar 348–353

Dementia

Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. Lawlor, Suppl 11, 5–10

Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. Rabinowitz, Oct 1329–1334

Clinical Effectiveness of Atypical Antipsychotics in Depression. Suppl 11, 1–31

Efficacy of atypical antipsychotics in elderly patients with dementia. Tariot, Suppl 11, 11–15

Introduction: clinical effectiveness of atypical antipsychotics in dementia. Tariot, Suppl 11, 3–4

Relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. Ballard, Suppl 11, 23–28

Depression

Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. Ninan, Mar 414–420

Anger in depressive mixed states [letter]. Benazzi; Mammen reply, Nov 1578–1579

Childhood maltreatment as a risk factor for adult cardiovascular disease and depression. Batten, Feb 249–254

Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. Lam, Mar 337–340

Clinical characteristics of depressive symptoms in children and adolescents with major depressive disorder. Yorbik, Dec 1654–1659

Common pathways of depression and pain. Delgado, Suppl 12, 16–20

Cost consequences of treatment-resistant depression. Russell, Mar 341–347

Daytime sleepiness and insomnia as correlates of depression. Fava, Suppl 16, 27–32

Depression and Physical Symptoms: The Mind-Body Connection [ACADEMIC HIGHLIGHTS]. June 867–876

Depressive disorders are related to nicotine dependence in the population but do not necessarily hamper smoking cessation. John, Feb 169–176
Double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Bielski, Sept 1190–1196
Duloxetine's role in the treatment of depression and associated painful physical symptoms [letter]. Wohlreich, July 1018–1019
Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. Trivedi, Oct 1356–1364
Effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Barbee, July 975–981
Effectiveness of St. John's wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. Gelenberg, Aug 1114–1119
Effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? Fava, Apr 521–530
Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. Grassi, Apr 515–520
Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. Birkenhäger, Nov 1505–1510
Enhancing Treatment Response in Depression. [Academic Highlights]. Sept 1269–1280
Escitalopram continuation treatment prevents relapse of depressive episodes. Rapaport, Jan 44–49
Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. Navarro, May 656–661
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert, Aug 1069–1075
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. Whyte, Dec 1634–1641
Higher levels of anger and aggressiveness in major depressive disorder than in anxiety and somatoform disorders [letter]. Picardi, Mar 442–443
Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. Frodl, Apr 492–499
History of major depressive disorder influences intent to die in violent suicide attempters. Astruc, May 690–695
Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. Hu, July 959–965
Introduction: postpartum depression. Freeman MP, Sept 1235
Introduction: the relationship of chronic pain and depression. Schatzberg, Suppl 12, 3–4
Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. Barbe, Jan 77–83
Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? Shelton CI, Suppl 17, 29–33
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. Joliat, Mar 373–378
Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. Gunderson, Aug 1049–1056
No deterioration of cognitive performance in an aggressive unilateral and bilateral antidepressant rTMS add-on trial. Hausmann, June 772–782
One-year follow-up after successful ECT: a naturalistic study in depressed inpatients. Birkenhäger, Jan 87–91
On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. Zimmerman, Oct 1400–1405
Open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. Schwartz TL, Sept 1223–1227
Pharmacologic Treatments of Major Depression: Are Two Mechanisms Really Better Than One? Suppl 4, 1–62
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. Perry, Feb 238–243
Plotting the course to remission: the search for better outcomes in the treatment of depression. Burt, Suppl 12, 20–25
Postpartum depression recurrence versus discontinuation syndrome: observations from a randomized controlled trial. Sunder, Sept 1266–1268
Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. Niedermaier, Dec 1619–1623
Psychopathology of seasonal affective disorder patients in comparison with major depression patients who have attempted suicide. Pendse, Mar 322–327
Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. Epperson, Mar 421–425
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. Papakostas, Aug 1090–1095
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. Papakostas, Aug 1096–1098
Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. Melartin, June 810–819
SNRIs in the management of acute major depressive disorder. Zajecka, Suppl 17, 11–18
Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. Papakostas, Apr 543–546
Specific characteristics of the pain/depression association in the general population. Ohayon, Suppl 12, 5–9
Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. Husain, Apr 485–491
3-Month, follow-up, randomized, placebo-controlled study of repetitive transcranial magnetic stimulation in depression. Koerselman, Oct 1323–1328
Treatment of postpartum depression, part 1: a critical review of biological interventions. Dennis, Sept 1242–1251
Treatment of postpartum depression, part 2: a critical review of nonbiological interventions. Dennis, Sept 1252–1265
Use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. Misri, Sept 1236–1241
Venlafaxine versus placebo in the preventive treatment of recurrent major depression. Montgomery, Mar 328–336
What characteristics of primary anxiety disorders predict subsequent major depressive disorder? Bittner, May 618–626
Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. Papakostas, Feb 217–221

Developmental Disorders

Retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. Corson, Nov 1531–1536

Diabetes

Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. Spoelstra, May 674–678
Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. Suppl 7, 1–20
Consensus development conference on antipsychotic drugs and obesity and diabetes. Feb 267–272
Development of guidelines for preventing and managing obesity and diabetes in mentally ill patients [letter]. Gupta S, Aug 1149
Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate [letter]. Ananth, May 724
Potential for detection bias in the association between olanzapine and diabetes [letter]. Compton; Caro reply, Feb 274–275
Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. Lamberti, May 702–706
Survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. Koller, June 857–863

Diagnosis

On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. Zimmerman, Oct 1400–1405

Dialectical Behavior Therapy
Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Simpson, Mar 379–385
Differential Diagnosis
Prepubertal bipolar I disorder and bipolar disorder NOS are separable from ADHD [editorial]. Post, July 898–902
Divalproex Sodium
Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. State, Aug 1057–1063
Dosing differences between valproic acid concentrate and divalproex sodium: a case report [letter]. Coffey, May 724–725
Possible role of divalproex sodium in sedation induced by antipsychotic medications [letter]. Berigan, Jan 133; Makela reply, Dec 1725
Dopamine
Cardiopulmonary complications of ergot-derivative dopamine agonists [letter]. Rack; Cavallaro reply, Oct 1429–1430
Role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. Denys, Suppl 14, 11–17
Dronabinol
Successful treatment of sexual dysfunction with dronabinol: a case report [letter]. Salerian, Aug 1146–1147
Drug Administration
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Currier, Mar 386–394
Drug Discontinuation
Postpartum depression recurrence versus discontinuation syndrome: observations from a randomized controlled trial. Sunder, Sept 1266–1268
Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. Pomerantz, Mar 395–404
3-Month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory median cutoff is a predictor of clinical outcome. Ballard, Jan 114–119
Drug Therapy, Combination
Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Bystritsky, Apr 565–568
Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. Lam, Mar 337–340
Double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Denys, Aug 1040–1048
Effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Barbee, July 975–981
Making optimal use of combination pharmacotherapy in bipolar disorder. Bowden, Suppl 15, 21–24
Measuring efficacy of polypharmacy in schizophrenic inpatients [letter]. Lindenmayer; McCue reply, Aug 1148
Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. Glick, May 679–685
Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. Bowden, May 707–714
DSM-IV
On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. Zimmerman, Oct 1400–1405
Duloxetine
Duloxetine's role in the treatment of depression and associated painful physical symptoms [letter]. Wohlreich, July 1018–1019
Effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? Fava, Apr 521–530
Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. Hirschfeld, Suppl 4, 46–52
Dyslipidemia
Dyslipidemia and atypical antipsychotic drugs. Casey, Suppl 18, 27–35
Eating Disorders see also specific disorders
Alcohol use disorder comorbidity in eating disorders: a multicenter study. Bulik, July 1000–1006
Serotonin function, personality-trait variations, and childhood abuse in women with bulimia-spectrum eating disorders. Steiger, June 830–837
Sleep-related eating disorder induced by risperidone [letter]. Lu M-L, Feb 273–274
Elderly
Efficacy of atypical antipsychotics in elderly patients with dementia. Tariot, Suppl 11, 11–15
Expert Consensus Guideline Series: Using Antipsychotic Agents in Older Patients, Suppl 2, 1–105
Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. Navarro, May 656–661
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. Whyte, Dec 1634–1641
Olanzapine may cause delirium in geriatric patients [letter]. Samuels, Apr 582–583
Tardive dyskinesia rates with atypical antipsychotics in older adults. Jeste, Suppl 9, 21–24
Electroconvulsive Therapy
Acetaminophen preferable to ibuprofen for pretreatment of electroconvulsive therapy–induced headache [letter]. Roth LS, May 726
Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. Navarro, May 656–661
One-year follow-up after successful ECT: a naturalistic study in depressed inpatients. Birkenhäger, Jan 87–91
Possible effects of ibuprofen pretreatment on seizure duration during electroconvulsive therapy [letter]. Kessler, Mar 442
Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. Husain, Apr 485–491
Escitalopram
Case of hyponatremia associated with escitalopram [letter]. Nahshoni, Dec 1722
Double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Bielski, Sept 1190–1196
Escitalopram continuation treatment prevents relapse of depressive episodes. Rapaport, Jan 44–49
Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. Hirschfeld, Suppl 4, 46–52
Estrogen
Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia [letter]. Rettenbacher, Feb 275–277
Expert Consensus Guidelines
Expert Consensus Guideline Series: Using Antipsychotic Agents in Older Patients, Suppl 2, 1–105
Extrapyramidal Symptoms
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. Baskys, Suppl 11, 16–22
Fatigue
Modafinil treatment for fatigue in HIV+ patients: a pilot study. Rabkin, Dec 1688–1695
Financial Support
Financial support for letter writing? [letter] Balon, May 721
Fluoxetine
Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Simpson, Mar 379–385
Effect of mirtazapine versus fluoxetine on "sleep quality" [letter]. Lawrence, Aug 1149–1150
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. Joliat, Mar 373–378
Preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Zanarini, July 903–907
Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. Papakostas, Apr 543–546
Fluvoxamine
Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Lu M-L, June 766–771
Folate
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. Papakostas, Aug 1090–1095
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. Papakostas, Aug 1096–1098
Forensic Psychiatry
Clinical and legal correlates of inmates with bipolar disorder at time of criminal arrest. Quanbeck, Feb 198–203

Psychiatric and legal features of 113 men convicted of sexual offenses. Dunsieth, Mar 293–300
Frontal Cerebral Perfusion
Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. Navarro, May 656–661
Gabapentin
Gabapentin reduces cocaine use among addicts from a community clinic sample. Raby, Jan 84–86
Galantamine
Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient [letter]. Arnold, Dec 1723–1724
Gastrointestinal Symptoms
Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder. Lydiard, June 838–844
Gender
Sex and psychiatry in the next 5 years [editorial]. Wisner, Apr 462–463
Variables associated with high olanzapine dosing in a state hospital. Botts, Aug 1138–1143
Generalized Anxiety Disorder
Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder. Lydiard, June 838–844
New Perspectives for Treating Generalized Anxiety Disorder. Suppl 13, 1–29
Primary care perspectives on generalized anxiety disorder. Roy-Byrne, Suppl 13, 20–26
Public health perspectives on generalized anxiety disorder. Stein MB, Suppl 13, 3–7
Selecting pharmacotherapy for generalized anxiety disorder. Goodman, Suppl 13, 8–13
Treating generalized anxiety disorder with cognitive-behavioral therapy. Lang, Suppl 13, 14–19
Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. Davidson, Suppl 5, 29–33
Gepirone
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert, Aug 1069–1075
Geriatric Psychiatry see Elderly
Glucose
Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. Newcomer, Suppl 18, 36–46
Effect of clozapine on factors controlling glucose homeostasis. Howes, Oct 1352–1355
Glycogen Synthase Kinase-3
Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. Gould, Jan 10–21
Gonadotropin-Releasing Hormone
Beneficial effects of gonadotropin-releasing hormone analogue treatment on positive and negative symptoms of schizophrenia: a case report [letter]. Soreni, July 1020–1021
Guidelines
Development of guidelines for preventing and managing obesity and diabetes in mentally ill patients [letter]. Gupta S, Aug 1149
Hallucinations see also specific types
Musical hallucinations: prevalence in psychotic and nonpsychotic outpatients. Hermesh, Feb 191–197
Visual hallucinations with sertraline [letter]. Marcon, Mar 446–447
Haloperidol
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Currier, Mar 386–394
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Zhang, July 940–947
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach, Mar 312–321
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Volavka J, Jan 57–61
Single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Emsley, May 696–701
Health Care Delivery
National trends in the outpatient treatment of anxiety disorders. Olfson, Sept 1166–1173
Hepatitis C Virus
Ribavirin may be an important factor in IFN-induced neuropsychiatric effects [letter]. Asnis; Kraus reply, Apr 581–582
Hippocampus
Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. Frodl, Apr 492–499
HIV
Modafinil treatment for fatigue in HIV+ patients: a pilot study. Rabkin, Dec 1688–1695
Use of newer antiretroviral treatments among HIV-infected Medicaid beneficiaries with serious mental illness. Walkup, Sept 1180–1189
Homocysteine
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. Papakostas, Aug 1090–1095
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. Papakostas, Aug 1096–1098
Homosexuality
Body-image dissatisfaction in gay versus heterosexual men: is there really a difference? Hausmann, Nov 1555–1558
Hormones
Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia [letter]. Rettenbacher, Feb 275–277
Metyrapone for delirium due to Cushing's syndrome induced by occult ectopic adrenocorticotropic hormone secretion [letter]. Kawashima, July 1019–1020
Relapse in pedophilic sex offending and subsequent suicide attempt during luteinizing hormone–releasing hormone treatment [letter]. Briken, Oct 1429
Hostility
Valproate for hostility in schizophrenia patients [letter]. Littrell, Jan 134
Hyperglycemia
Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. Suppl 7, 1–20
Incidence of hyperglycemia in patients treated with olanzapine [letter]. Misawa, Mar 443–444
Survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. Koller, June 857–863
Hyperlipidemia
Hyperlipidemia in persons using antipsychotic medication: a general population–based birth cohort study. Saari, Apr 547–550
Hyperproinsulinemia
Transient hyperproinsulinemia during treatment with clozapine and amisulpride [letter]. Rettenbacher, June 878–879
Hyperprolactinemia
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. Cavallaro, Feb 187–190
Case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics [letter]. Toki, Nov 1576–1577
Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. Montgomery, Nov 1491–1498
Hypertension
Clozapine and hypertension: a chart review of 82 patients. Henderson, May 686–689
Hypnotics and Sedatives
Pharmacologic management of daytime sleepiness. Schwartz JRL, Suppl 16, 46–49
Pharmacologic management of insomnia. Walsh, Suppl 16, 41–45
Use of trazodone as a hypnotic: a critical review. James, June 752–755
Hypoestrogenemia
Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia [letter]. Rettenbacher, Feb 275–277
Hyponatremia
Case of hyponatremia associated with escitalopram [letter]. Nahshoni, Dec 1722
Ibuprofen
Acetaminophen preferable to ibuprofen for pretreatment of electroconvulsive therapy–induced headache [letter]. Roth LS, May 726
Possible effects of ibuprofen pretreatment on seizure duration during electroconvulsive therapy [letter]. Kessler, Mar 442
Immune System
In the puerperium, primiparae exhibit higher levels of anxiety and serum peptidase activity and greater immune responses than multiparae. Maes, Jan 71–76

Immunoglobulins
Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. Hoekstra, Apr 537–542
Infants
Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. Berle, Sept 1228–1234
Bupropion and breastfeeding: a case of a possible infant seizure [letter]. Chaudron, June 881–882
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Oberlander, Feb 230–237
Insomnia
Assessment of excessive sleepiness and insomnia as they relate to circadian rhythm sleep disorders. Doghramji K, Suppl 16, 17–22
Changing How We Think About Insomnia: Confronting Clinical Challenges. Suppl 8, 1–49
Changing perspective on chronic insomnia management. Krystal, Suppl 8, 20–25
Classifying insomnia in a clinically useful way. Edinger, Suppl 8, 36–43
Clinical and socioeconomic correlates of insomnia. Walsh, Suppl 8, 13–19
Cognitive-behavioral approaches to the treatment of insomnia. Morin, Suppl 16, 33–40
Daytime sleepiness and insomnia as correlates of depression. Fava, Suppl 16, 27–32
Introduction: definitions, measurements, and management in insomnia. Krystal, Suppl 8, 5–7
Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. Perlis, Aug 1128–1137
Measuring treatment efficacy in insomnia. Roth T, Suppl 8, 8–12
Panel discussion: changing how we think about insomnia. Suppl 8, 44–46
Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. Benca, Suppl 8, 26–35
Insulin
Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. Arranz, Oct 1335–1342
Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO)
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach, Mar 312–321
Interferon
Ribavirin may be an important factor in IFN-induced neuropsychiatric effects [letter]. Asnis; Kraus reply, Apr 581–582
Interleukin
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Zhang, July 940–947
Intermittent Explosive Disorder
Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. Coccaro, June 820–824
International Consensus Group on Bipolar I Depression
International Consensus Group on Bipolar I Depression Treatment Guidelines [ACADEMIC HIGHLIGHTS]. Apr 569–579
International Consensus Group on Depression and Anxiety
Consensus statement update on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 1, 55–62
Israel
Body mass index and future schizophrenia in Israeli male adolescents. Weiser, Nov 1546–1549
Japan
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. Yamashita, Nov 1525–1530
Journal of Clinical Psychiatry
Introducing PubWeb™ [Publisher's Note]. Oct 1300
Medical education: our mission and our success. Feb 147–148
Our reviewers [editorial]. Gelenberg SJ, Jan 4–7
Stability in a time of uncertainty [Publisher's Note]. July 896–897
The *Journal* in 2004 [editorial]. Gelenberg, Dec 1593–1596
Kidney Failure
Renal insufficiency in long-term lithium treatment. Lepkifker, June 850–856
Kleptomania
Case of kleptomania correlating with premenstrual dysphoria [letter]. Aboujaoude, May 725–726
Lamotrigine
Current understanding of lamotrigine as a mood stabilizer. Hahn, June 791–804
Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. Khan, Nov 1483–1490
52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. McElroy, Feb 204–210
Pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Goodwin, Mar 432–441
Two cases of acneiform eruption associated with lamotrigine [letter]. Nielsen, Dec 1720–1722
Leptin
Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. Arranz, Oct 1335–1342
Levetiracetam
Open-label study of levetiracetam for the treatment of social anxiety disorder. Simon, Sept 1219–1222
Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator [BRAINSTORMS]. Stahl, Sept 1162–1163
Lewy Body Dementia
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. Baskys, Suppl 11, 16–22
Life Events
Association of small life events with self reports of tic severity in pediatric and adult tic disorder patients: a prospective longitudinal study. Hoekstra, Mar 426–431
Literature Search
Searching the medical literature for case reports [letter]. Mago; Gupta N reply, Mar 444–446
Lithium
Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. State, Aug 1057–1063
Correlates of suicidal behavior and lithium treatment in bipolar disorder. Dunner, Suppl 10, 5–10
Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate [letter]. Ananth, May 724
Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Leucht, Feb 177–186
Novel, point-of-care test for lithium levels: description and reliability. Glazer, May 652–655
Pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Goodwin, Mar 432–441
Renal insufficiency in long-term lithium treatment. Lepkifker, June 850–856
Lorazepam
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Currier, Mar 386–394
Lupus Erythematosus
Prevalence of obsessive-compulsive disorder in patients with systemic lupus erythematosus. Slattery, Mar 301–306
Magnetoencephalography
Limbic paroxysmal magnetoencephalographic activity in 12 obsessive-compulsive disorder patients: a new diagnostic finding. Amo, Feb 156–162
Mania
Antidepressant-withdrawal mania: a critical review and synthesis of the literature. Andrade, July 987–993
Can bilateral prefrontal repetitive transcranial magnetic stimulation (rTMS) induce mania? a case report [letter]. Hausmann, Nov 1575–1576
Case report of mania related to discontinuation of bupropion therapy for smoking cessation [letter]. Michael, Feb 277
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. Rachid, Nov 1537–1545
Psychosis in mania: specificity of its role in severity and treatment response. Swann AC, June 825–829
Single-dose intravenous valproate in acute mania. Phrolov, Jan 68–70
Massachusetts General Hospital
Development of clonazepam as a psychotropic: the Massachusetts General Hospital experience. Rosenbaum, Suppl 5, 3–6
Maternity
In the puerperium, primiparae exhibit higher levels of anxiety and serum peptidase activity and greater immune responses than multiparae. Maes, Jan 71–76

McLeod-Neuroacanthocytosis Syndrome
Schizophrenia as a manifestation of X-linked McLeod-neuroacanthocytosis syndrome [letter]. Jung, May 722–723
Meclizine
Successful use of meclizine in panic disorder [letter]. Sansone, Sept 1285–1286
Medical Illness
Association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. Frankenburg, Dec 1660–1665
Medication Adherence
Adherence to conventional and atypical antipsychotics after hospital discharge. Diaz, Mar 354–360
Pilot study of barriers to medication adherence in schizophrenia. Hudson, Feb 211–216
Medicine
Honoring our evidence base [commentary]. Gelenberg, June 750–751
Medicine: the coming challenges and opportunities [editorial]. Culpepper, June 740–741
Men
Body-image dissatisfaction in gay versus heterosexual men: is there really a difference? Hausmann, Nov 1555–1558
Open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. Aviv, Jan 97–103
Mental Health Service Utilization
Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. Zanarini, Jan 28–36
Mental Illness
Computer-assisted self-assessment in persons with severe mental illness. Chinman, Oct 1343–1351
Use of newer antiretroviral treatments among HIV-infected Medicaid beneficiaries with serious mental illness. Walkup, Sept 1180–1189
Mental Retardation
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Aman, Sept 1197–1210
Meta-Analysis
Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Leucht, Feb 177–186
Metabolic Issues
Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Lu M-L, June 766–771
Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. Suppl 7, 1–20
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. Alméras, Apr 557–564
Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. Misra, Dec 1607–1618
Metabolic effects of treatment with atypical antipsychotics [commentary]. Kane, Nov 1447–1455
Metabolic Issues in Patients With Psychiatric Disorders. Suppl 18, 1–56
Metabolic syndrome: epidemiology and consequences. Sacks, Suppl 18, 3–12
Metyrapone
Metyrapone for delirium due to Cushing's syndrome induced by occult ectopic adrenocorticotropic hormone secretion [letter]. Kawashima, July 1019–1020
Mirtazapine
Effect of mirtazapine versus fluoxetine on "sleep quality" [letter]. Lawrence, Aug 1149–1150
Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. Niedermaier, Dec 1619–1623
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Pallanti, Oct 1394–1399
Modafinil
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. Ninan, Mar 414–420
Modafinil and antipsychotic-induced sedation [letter]. DeQuardo; Makela reply, Feb 278–279
Modafinil treatment for fatigue in HIV+ patients: a pilot study. Rabkin, Dec 1688–1695
Open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. Schwartz TL, Sept 1223–1227
Pharmacologic management of daytime sleepiness. Schwartz JRL, Suppl 16, 46–49
Pharmacologic management of insomnia. Walsh, Suppl 16, 41–45
Molecular Medicine
Molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry [editorial]. Gould, May 598–604
Monoamine Oxidase Inhibitors
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. Feinberg, Nov 1520–1524
Montgomery-Asberg Depression Rating Scale
Defining remission on the Montgomery-Asberg Depression Rating Scale. Zimmerman, Feb 163–168
Mood Disorders
Are mood disorders and obesity related? a review for the mental health professional. McElroy, May 634–651
Mood Stabilizers
Anger attacks in bipolar depression: predictors and response to citalopram added to mood stabilizers. Mammen, May 627–633
Current understanding of lamotrigine as a mood stabilizer. Hahn, June 791–804
Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. Bowden, May 707–714
Motor Conversion Disorders
Motor conversion disorders reviewed from a neuropsychiatric perspective. Krem, June 783–790
Movement Disorders
Drug-Induced Movement Disorders, Suppl 9, 1–31
Historical perspective on movement disorders. Friedman, Suppl 9, 3–8
New nomenclature for drug-induced movement disorders including tardive dyskinesia. Chouinard, Suppl 9, 9–15
Pathophysiology of antipsychotic drug–induced movement disorders. Casey, Suppl 9, 25–28
Musical Hallucinations
Musical hallucinations: prevalence in psychotic and nonpsychotic outpatients. Hermesh, Feb 191–197
Myocardial Infarction
Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate [letter]. Ananth, May 724
Naltrexone
Naltrexone in the treatment of adolescent sexual offenders. Ryback, July 982–986
National Epidemiologic Survey on Alcohol and Related Conditions
Prevalence, correlates, and disability of personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Grant, July 948–958
Nefazodone
Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. Wetzel, Oct 1406–1413
Neuroleptic Malignant Syndrome
Catatonia is a risk factor for neuroleptic malignant syndrome [letter]. Carroll, Dec 1722–1723
Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate [letter]. Ananth, May 724
Neuroleptic malignant syndrome and atypical antipsychotic drugs. Ananth, Apr 464–470
Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome [letter]. Atbasoglu, Dec 1724–1725
Neuropeptides
In the puerperium, primiparae exhibit higher levels of anxiety and serum peptidase activity and greater immune responses than multiparae. Maes, Jan 71–76
Neuropsychiatric Inventory
3-Month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory median cutoff is a predictor of clinical outcome. Ballard, Jan 114–119
Neuroscience
Molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry [editorial]. Gould, May 598–604
Neurosyphilis
Neurosyphilis in newly admitted psychiatric patients: three case reports. Saik, July 919–921

New York City
Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. Leon, July 915–918
Nicotine
Depressive disorders are related to nicotine dependence in the population but do not necessarily hamper smoking cessation. John, Feb 169–176
9/11
Science for the community: assessing mental health after 9/11. Marshall, Suppl 1, 37–43
Nomenclature
New nomenclature for drug-induced movement disorders including tardive dyskinesia. Chouinard, Suppl 9, 9–15
Norepinephrine
Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. Lucki, Suppl 4, 11–24
Obesity see Weight
Obsessive-Compulsive Disorder
Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Bystritsky, Apr 565–568
Beyond Refractory Obsessions and Anxiety States: Toward Remission. Suppl 14, 1–36
Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list–controlled open trial. Tolin, July 922–931
Double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Denys, Aug 1040–1048
Double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. Denys, Jan 37–43
Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. Diniz, Jan 22–27
Introduction. Beyond refractory obsessions and anxiety states: toward remission. Hollander, Suppl 14, 3–5
Limbic paroxysmal magnetoencephalographic activity in 12 obsessive-compulsive disorder patients: a new diagnostic finding. Amo, Feb 156–162
Obsessive-compulsive spectrum disorders in rheumatic fever with and without Sydenham's chorea. Hounie, July 994–999
Prevalence of obsessive-compulsive disorder in patients with systemic lupus erythematosus. Slattery, Mar 301–306
Qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. Pallanti, Suppl 14, 6–10
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Pallanti, Oct 1394–1399
Role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. Denys, Suppl 14, 11–17
Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. Zohar, Suppl 14, 18–21
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. Maina, Oct 1365–1371
Off-Label Usage
Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. Pomerantz, Mar 395–404
Olanzapine
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Lee E, June 864–866
Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Bystritsky, Apr 565–568
Case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics [letter]. Toki, Nov 1576–1577
Comments on cost analysis of risperidone versus olanzapine [letter]. Duggal; Taylor reply, June 879–880
Comparison of rapid-cycling and non–rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. Vieta, Oct 1420–1428
Comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. McQuade, Suppl 18, 47–56
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. Mulsant, Dec 1708–1714
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach, Mar 312–321
Effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Barbee, July 975–981
Incidence of hyperglycemia in patients treated with olanzapine [letter]. Misawa, Mar 443–444
Olanzapine may cause delirium in geriatric patients [letter]. Samuels, Apr 582–583
Olanzapine versus placebo in the treatment of borderline personality disorder. Bogenschutz, Jan 104–109
Open trial of olanzapine in anorexia nervosa. Barbarich, Nov 1480–1482
Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. Glick, May 679–685
Possible impact of dropout in a study of high-dose olanzapine and prolactin levels [letter]. Andrade; Karagianis reply, Aug 1150
Potential for detection bias in the association between olanzapine and diabetes [letter]. Compton; Caro reply, Feb 274–275
Preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Zanarini, July 903–907
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Volavka J, Jan 57–61
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. Swanson, Dec 1666–1673
Variables associated with high olanzapine dosing in a state hospital. Botts, Aug 1138–1143
Weight gain during treatment of bipolar I patients with olanzapine. Hennen, Dec 1679–1687
Olanzapine-Fluoxetine Combination
Preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Zanarini, July 903–907
Outcome
Plotting the course to remission: the search for better outcomes in the treatment of depression. Burt, Suppl 12, 20–25
Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization. Arnow, Suppl 12, 10–15
Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. Krell, Sept 1174–1179
3-Month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory median cutoff is a predictor of clinical outcome. Ballard, Jan 114–119
Outpatients
Adherence to conventional and atypical antipsychotics after hospital discharge. Diaz, Mar 354–360
Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. Freudenreich, Oct 1372–1376
National trends in the outpatient treatment of anxiety disorders. Olfson, Sept 1166–1173
Pain
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as $\alpha_2\delta$ ligands at voltage-gated calcium channels [BRAINSTORMS]. Stahl, May 596–597
Common pathways of depression and pain. Delgado, Suppl 12, 16–20
Duloxetine's role in the treatment of depression and associated painful physical symptoms [letter]. Wohlreich, July 1018–1019
Effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? Fava, Apr 521–530
Introduction: the relationship of chronic pain and depression. Schatzberg, Suppl 12, 3–4
Preemptive analgesia: is pain less costly when you pre-pay for it? [BRAINSTORMS] Stahl, Dec 1591–1592
Specific characteristics of the pain/depression association in the general population. Ohayon, Suppl 12, 5–9
Venlafaxine XR and chronic pelvic pain syndrome [letter]. Karp, June 880–881
Panic Disorder
Identifying and treating panic disorder in primary care. Culpepper, Suppl 5, 19–23

Long-term management of panic disorder. Doyle, Suppl 5, 24–28
Overview of panic and social anxiety disorders. Westenberg, Suppl 14, 22–26
Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. Bandelow, Mar 405–413
Successful use of meclizine in panic disorder [letter]. Sansone, Sept 1285–1286

Parkinson's Disease
Psychiatric complications of deep brain stimulation for Parkinson's disease. Piasecki, June 845–849

Paroxetine
Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Lepola, Feb 222–229
Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Seedat, Feb 244–248
Double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. Denys, Jan 37–43
Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. Trivedi, Oct 1356–1364
Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. Leon, July 915–918
Remission rates in patients with anxiety disorders treated with paroxetine. Ballenger, Dec 1696–1707
Risperidone and paroxetine given singly and in combination for bipolar depression. Shelton RC, Dec 1715–1719
Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. Bandelow, Mar 405–413
Use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. Misri, Sept 1236–1241

Patient Attitudes
Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. Freudenreich, Oct 1372–1376
Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. Rettenbacher, Sept 1211–1218
Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. Krell, Sept 1174–1179

Pedophilia
Relapse in pedophilic sex offending and subsequent suicide attempt during luteinizing hormone–releasing hormone treatment [letter]. Briken, Oct 1429

Perospirone
Two cases of perospirone-induced mania in schizophrenia [letter]. Yokoshima, Jan 135

Personality Disorders
Prevalence, correlates, and disability of personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Grant, July 948–958

Peyote
Case of prolonged peyote-induced psychosis resolved by sleep [letter]. Lu BY, Oct 1433–1434

Pharmacology
Are two antidepressant mechanisms better than one? issues in clinical trial design and analysis. Leon, Suppl 4, 31–36
Debate and discussion: in the treatment of depression, does selectivity of action matter? Suppl 4, 60–62
Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. Lucki, Suppl 4, 11–24
How antidepressants help depression: mechanisms of action and clinical response. Delgado, Suppl 4, 25–30
Introduction. Pharmacologic treatments of major depression: are two mechanisms really better than one? Schatzberg, Suppl 4, 3–4
Selective versus multi-transmitter antidepressants: are two mechanisms better than one? Burke, Suppl 4, 37–45
Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. Owens, Suppl 4, 5–10

Pharmacotherapy
Selecting pharmacotherapy for generalized anxiety disorder. Goodman, Suppl 13, 8–13

Phenelzine
Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. Birkenhäger, Nov 1505–1510

Phenytoin
Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. Bremner, Nov 1559–1564

Phototherapy see Bright Light Therapy

Physical Symptoms
Depression and Physical Symptoms: The Mind-Body Connection [Academic Highlights]. June 867–876
Duloxetine's role in the treatment of depression and associated painful physical symptoms [letter]. Wohlreich, July 1018–1019
Effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? Fava, Apr 521–530
Recognizing the Physical Symptoms of Depression. Suppl 12, 1–28

Physician-Patient Relations
Medicine: the coming challenges and opportunities [editorial]. Culpepper, June 740–741

Physician Practice Patterns
Variables associated with high olanzapine dosing in a state hospital. Botts, Aug 1138–1143

Physician Survey
Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. Pomerantz, Mar 395–404

Pindolol
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. Perry, Feb 238–243

Polypharmacy see Drug Therapy, Combination

Posttraumatic Stress Disorder
Consensus statement update on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 1, 55–62
Introduction: update on posttraumatic stress disorder. Ballenger, Suppl 1, 3
Long-term treatment and prevention of posttraumatic stress disorder. Davidson, Suppl 1, 44–48
Neurobiological consequences of childhood trauma. Nemeroff, Suppl 1, 18–28
Posttraumatic stress disorder as a result of mass trauma. Shalev, Suppl 1, 4–10
Posttraumatic stress disorder in primary care: a hidden diagnosis. Lecrubier, Suppl 1, 49–54
Preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Reich, Dec 1601–1606
Risk and resilience in posttraumatic stress disorder. Yehuda, Suppl 1, 29–36
Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. Perkonigg, Oct 1314–1322
Science for the community: assessing mental health after 9/11. Marshall, Suppl 1, 37–43
Severe acute respiratory syndrome–related psychiatric and posttraumatic morbidities and coping responses in medical staff within a primary health care setting in Singapore. Sim, Aug 1120–1127
Structural and functional brain changes in posttraumatic stress disorder. Nutt, Suppl 1, 11–17
Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. Bremner, Nov 1559–1564
Update on Posttraumatic Stress Disorder. Suppl 1, 1–62
Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. Davidson, Suppl 5, 29–33

Prediction
Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? Kleindienst, July 966–974
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. Papakostas, Aug 1090–1095
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. Papakostas, Aug 1096–1098
Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. Weinmann, Aug 1099–1105

Pregnancy
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Oberlander, Feb 230–237
Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. Epperson, Mar 421–425

Premenstrual Dysphoric Disorder
Case of kleptomania correlating with premenstrual dysphoria [letter]. Aboujaoude, May 725–726

Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. Perkonigg, Oct 1314–1322
Withdrawal reactions associated with low-dose venlafaxine treatment in a patient with premenstrual dysphoric disorder [letter]. Hsiao, Aug 1147–1148
Prenatal Exposure
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Oberlander, Feb 230–237
Prescriptions
Rose by any other name [letter]. Sutor, Apr 584
Primary Care
Diagnosis and treatment of ADHD in adults in primary care. Montano, Suppl 3, 18–21
Identifying and treating panic disorder in primary care. Culpepper, Suppl 5, 19–23
Posttraumatic stress disorder in primary care: a hidden diagnosis. Lecrubier, Suppl 1, 49–54
Primary care perspectives on generalized anxiety disorder. Roy-Byrne, Suppl 13, 20–26
Recognizing sleep disorders in a primary care setting. Doghramji PP, Suppl 16, 23–26
Severe acute respiratory syndrome–related psychiatric and posttraumatic morbidities and coping responses in medical staff within a primary health care setting in Singapore. Sim, Aug 1120–1127
Progesterone
Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia [letter]. Rettenbacher, Feb 275–277
Prolactin
Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. Misra, Dec 1607–1618
Possible impact of dropout in a study of high-dose olanzapine and prolactin levels [letter]. Andrade; Karagianis reply, Aug 1150
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Volavka J, Jan 57–61
Propofol
Use of propofol for alcohol withdrawal delirium: a case report [letter]. Takeshita, Jan 134–135
Psychiatry
Honoring our evidence base [commentary]. Gelenberg, June 750–751
Medicine: the coming challenges and opportunities [editorial]. Culpepper, June 740–741
Sex and psychiatry in the next 5 years [editorial]. Wisner, Apr 462–463
Psychosis
Atypical Antipsychotics in the Treatment of Children and Adolescents. Suppl 6, 1–44
Case of prolonged peyote-induced psychosis resolved by sleep [letter]. Lu BY, Oct 1433–1434
Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia [letter]. Rettenbacher, Feb 275–277
Musical hallucinations: prevalence in psychotic and nonpsychotic outpatients. Hermesh, Feb 191–197
Psychosis in mania: specificity of its role in severity and treatment response. Swann AC, June 825–829
Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? [letter] Duggal; Hofer reply, Aug 1145–1146
Sex differences in emotional reactivity to daily life stress in psychosis. Myin-Germeys, June 805–809
Psychotropic Medication
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Oberlander, Feb 230–237
Public Health
Public health perspectives on generalized anxiety disorder. Stein MB, Suppl 13, 3–7
Quality of Life
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Nasrallah, Apr 531–536; Correction, Aug 1150
Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. Hofer, July 932–939
Questionnaires
Response to commentary: "using questionnaires to screen for psychiatric disorders." [letter] Hirschfeld, May 721–722
Using questionnaires to screen for psychiatric disorders: a comment on a study of screening for bipolar disorder in the community [commentary]. Zimmerman, May 605–610
Quetiapine
Case of tardive dystonia successfully managed with quetiapine [letter]. Sasaki, Apr 583–584
Double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Denys, Aug 1040–1048
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach, Mar 312–321
Effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Barbee, July 975–981
Retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. Corson, Nov 1531–1536
Single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Emsley, May 696–701
Survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. Koller, June 857–863
Rating Scales
Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. Murphy, Suppl 3, 12–17
Reboxetine
Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. Grassi, Apr 515–520
Remission
Defining remission on the Montgomery-Asberg Depression Rating Scale. Zimmerman, Feb 163–168
Remission versus response: the new gold standard of antidepressant care. Keller, Suppl 4, 53–59
Renal Function
Renal insufficiency in long-term lithium treatment. Lepkifker, June 850–856
Respiratory Infections
Respiratory infections rather than antibiotics may increase clozapine levels: a critical review of the literature [letter]. de Leon, Aug 1144–1145
Rheumatic Fever
Obsessive-compulsive spectrum disorders in rheumatic fever with and without Sydenham's chorea. Hounie, July 994–999
Ribavirin
Ribavirin may be an important factor in IFN-induced neuropsychiatric effects [letter]. Asnis; Kraus reply, Apr 581–582
Risk Factors
Potential for detection bias in the association between olanzapine and diabetes [letter]. Compton; Caro reply, Feb 274–275
Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. Perkonigg, Oct 1314–1322
Risperidone
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Currier, Mar 386–394
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Lee E, June 864–866
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. Rabinowitz, Oct 1329–1334
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. Cavallaro, Feb 187–190
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Zhang, July 940–947
Comments on cost analysis of risperidone versus olanzapine [letter]. Duggal; Taylor reply, June 879–880
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. Mulsant, Dec 1708–1714
Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate [letter]. Ananth, May 724
Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. Taylor, Aug 1076–1083
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach, Mar 312–321
Effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Barbee, July 975–981

Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Addington, Dec 1624–1633
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Nasrallah, Apr 531–536; Correction, Aug 1150
Open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. Aviv, Jan 97–103
Preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Reich, Dec 1601–1606
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Volavka J, Jan 57–61
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. Swanson, Dec 1666–1673
Risperidone and paroxetine given singly and in combination for bipolar depression. Shelton RC, Dec 1715–1719
Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. Bowden, May 707–714
Risperidone in the treatment of delirium: results from a prospective open-label trial. Mittal, May 662–667
Risperidone in the treatment of patients with delirium. Parellada, Mar 348–353
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Lindenmayer, Aug 1084–1089
Sleep-related eating disorder induced by risperidone [letter]. Lu M-L, Feb 273–274
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Aman, Sept 1197–1210

Schizoaffective Disorder

Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Addington, Dec 1624–1633

Schizophrenia

Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient [letter]. Arnold, Dec 1723–1724
Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. Suppl 7, 1–20
Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. Freudenreich, Oct 1372–1376
Beneficial effects of gonadotropin-releasing hormone analogue treatment on positive and negative symptoms of schizophrenia: a case report [letter]. Soreni, July 1020–1021
Body mass index and future schizophrenia in Israeli male adolescents. Weiser, Nov 1546–1549
Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Curkendall, May 715–720
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Zhang, July 940–947
Clinicians' reasons for antipsychotic coprescribing. Sernyak, Dec 1597–1600
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Harvey, Mar 361–372
Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. Rettenbacher, Sept 1211–1218
Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. Taylor, Aug 1076–1083
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach, Mar 312–321
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. Lindenmayer, Apr 551–556
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. Yamashita, Nov 1525–1530
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Addington, Dec 1624–1633
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Nasrallah, Apr 531–536; Correction, Aug 1150
Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. Arranz, Oct 1335–1342
Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Leucht, Feb 177–186
Measuring efficacy of polypharmacy in schizophrenic inpatients [letter]. Lindenmayer; McCue reply, Aug 1148
Open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. Aviv, Jan 97–103
Pilot study of barriers to medication adherence in schizophrenia. Hudson, Feb 211–216
Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. Montgomery, Nov 1491–1498
Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Ganguly, Oct 1377–1388
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Volavka J, Jan 57–61
Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. Hofer, July 932–939
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. Swanson, Dec 1666–1673
Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. Sevy, June 756–765
Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. Bellino, July 908–914
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Lindenmayer, Aug 1084–1089
Schizophrenia and binge-eating disorders [letter]. Ramacciotti, July 1016–1017
Schizophrenia and obesity: impact of antipsychotic medications. Wirshing, Suppl 18, 13–26
Schizophrenia as a manifestation of X-linked McLeod-neuroacanthocytosis syndrome [letter]. Jung, May 722–723
Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. Weinmann, Aug 1099–1105
Symptoms and circuits, pt 3: schizophrenia [BRAINSTORMS]. Stahl, Jan 8–9
Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Miller, Apr 500–508
Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. Evins, Mar 307–311
Valproate for hostility in schizophrenia patients [letter]. Littrell, Jan 134

Seasonal Affective Disorder

Psychopathology of seasonal affective disorder patients in comparison with major depression patients who have attempted suicide. Pendse, Mar 322–327
Seasonality of birth in seasonal affective disorder. Pjrek, Oct 1389–1393

Sedation

Modafinil and antipsychotic-induced sedation [letter]. DeQuardo; Makela reply, Feb 278–279
Open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. Schwartz TL, Sept 1223–1227
Possible role of divalproex sodium in sedation induced by antipsychotic medications [letter]. Berigan, Jan 133; Makela reply, Dec 1725

Selective Serotonin Reuptake Inhibitors

Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. Ninan, Mar 414–420
Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. Ramasubbu, Dec 1642–1653
"Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. Damsa, Aug 1064–1068

Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. Whyte, Dec 1634–1641
Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. Hu, July 959–965
Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? Shelton CI, Suppl 17, 29–33
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. Perry, Feb 238–243
Placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor–induced sexual dysfunction. Clayton, Jan 62–67
Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. Papakostas, Feb 217–221

Self-Injurious Behavior
Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Philipsen, Oct 1414–1419

Serotonin
Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. Lucki, Suppl 4, 11–24
Serotonin function, personality-trait variations, and childhood abuse in women with bulimia-spectrum eating disorders. Steiger, June 830–837
Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. Zohar, Suppl 14, 18–21

Serotonin-Norepinephrine Reuptake Inhibitors
Dual-action hypothesis: does pharmacology matter? Shelton RC, Suppl 17, 5–10
Introduction. The dual-action debate: does pharmacology matter? Thase, Suppl 17, 3–4
Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? Shelton CI, Suppl 17, 29–33
Qualitative review of SNRIs in anxiety. Silverstone, Suppl 17, 19–28
SNRIs in the management of acute major depressive disorder. Zajecka, Suppl 17, 11–18

Serotonin Reuptake Inhibitors
Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Bystritsky, Apr 565–568
Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. Berle, Sept 1228–1234
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. Maina, Oct 1365–1371

Sertraline
Postpartum depression recurrence versus discontinuation syndrome: observations from a randomized controlled trial. Sunder, Sept 1266–1268
Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. Bandelow, Mar 405–413
Visual hallucinations with sertraline [letter]. Marcon, Mar 446–447

Severe Acute Respiratory Syndrome (SARS)
Severe acute respiratory syndrome–related psychiatric and posttraumatic morbidities and coping responses in medical staff within a primary health care setting in Singapore. Sim, Aug 1120–1127

Sex Factors
Sex differences in emotional reactivity to daily life stress in psychosis. Myin-Germeys, June 805–809

Sex Offenders
Naltrexone in the treatment of adolescent sexual offenders. Ryback, July 982–986
Psychiatric and legal features of 113 men convicted of sexual offenses. Dunsieth, Mar 293–300

Sexual Abuse
Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. Barbe, Jan 77–83
Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization. Arnow, Suppl 12, 10–15

Sexual Dysfunction
Open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. Aviv, Jan 97–103
Placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor–induced sexual dysfunction. Clayton, Jan 62–67
Successful treatment of sexual dysfunction with dronabinol: a case report [letter]. Salerian, Aug 1146–1147

Sildenafil
Open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. Aviv, Jan 97–103

Singapore
Severe acute respiratory syndrome–related psychiatric and posttraumatic morbidities and coping responses in medical staff within a primary health care setting in Singapore. Sim, Aug 1120–1127

Sleep
Case of prolonged peyote-induced psychosis resolved by sleep [letter]. Lu BY, Oct 1433–1434
Characteristics and determinants of normal sleep. Roth T, Suppl 16, 8–11
Differential Diagnosis and Management of Daytime Sleepiness and Nighttime Wakefulness. Suppl 16, 1–52
Effect of mirtazapine versus fluoxetine on "sleep quality" [letter]. Lawrence, Aug 1149–1150
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. Yamashita, Nov 1525–1530
Neurotransmitters of sleep. Siegel, Suppl 16, 4–7
Sleepiness Versus Sleeplessness: Shift Work and Sleep Disorders [ACADEMIC HIGHLIGHTS]. July 1007–1015
Sleep-related eating disorder induced by risperidone [letter]. Lu M-L, Feb 273–274

Sleep Disorders
Assessment of excessive sleepiness and insomnia as they relate to circadian rhythm sleep disorders. Doghramji K, Suppl 16, 17–22
Daytime sleepiness and insomnia as correlates of depression. Fava, Suppl 16, 27–32
Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. Young, Suppl 16, 12–16
Pharmacologic management of daytime sleepiness. Schwartz JRL, Suppl 16, 46–49
Recognizing sleep disorders in a primary care setting. Doghramji PP, Suppl 16, 23–26

Smoking
Case report of mania related to discontinuation of bupropion therapy for smoking cessation [letter]. Michael, Feb 277
Depressive disorders are related to nicotine dependence in the population but do not necessarily hamper smoking cessation. John, Feb 169–176
Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. Evins, Mar 307–311
Variables associated with high olanzapine dosing in a state hospital. Botts, Aug 1138–1143

Social Anxiety Disorder
Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Lepola, Feb 222–229
Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Seedat, Feb 244–248
Open-label study of levetiracetam for the treatment of social anxiety disorder. Simon, Sept 1219–1222
Overview of panic and social anxiety disorders. Westenberg, Suppl 14, 22–26
Social anxiety disorder spectrum. Stein DJ, Suppl 14, 27–33
Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. Davidson, Suppl 5, 29–33

Social Phobia
Open trial of topiramate in the treatment of generalized social phobia. Van Ameringen, Dec 1674–1678

Sodium Channels
Mechanism of action of voltage sensitive sodium channel modulators [BRAINSTORMS]. Stahl, July 894–895

Somatoform Disorders
Higher levels of anger and aggressiveness in major depressive disorder than in anxiety and somatoform disorders [letter]. Picardi, Mar 442–443
Motor conversion disorders reviewed from a neuropsychiatric perspective. Krem, June 783–790
Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. Papakostas, Apr 543–546

State Hospitals
Variables associated with high olanzapine dosing in a state hospital. Botts, Aug 1138–1143

Statistical Analysis
Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments. Leon, Nov 1511–1514
Stevens-Johnson Syndrome
Possible case of venlafaxine-induced Stevens-Johnson syndrome [letter]. Weiss NT, Oct 1431–1433
Stimulants
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. Feinberg, Nov 1520–1524
St. John's Wort
Adverse effects of St. John's wort: a systematic review. Knüppel, Nov 1470–1479
Effectiveness of St. John's wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. Gelenberg, Aug 1114–1119
How effective is St. John's wort? the evidence revisited. Werneke, May 611–617
Stroke
Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. Niedermaier, Dec 1619–1623
Study Design
Possible impact of dropout in a study of high-dose olanzapine and prolactin levels [letter]. Andrade; Karagianis reply, Aug 1150
Substance Abuse
Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. Clark, Feb 151–155
Impact of ADHD and its treatment on substance abuse in adults. Wilens, Suppl 3, 38–45
Prescribing benzodiazepines for patients with substance use disorders [letter]. Lieberman; Clark reply, Nov 1577–1578
Suicide
Antidepressants and suicide risk in the United States, 1985–1999. Grunebaum, Nov 1456–1462
Bipolar patients with suicidal behavior: toward the identification of a clinical subgroup. Slama, Aug 1035–1039
Correlates of suicidal behavior and lithium treatment in bipolar disorder. Dunner, Suppl 10, 5–10
History of major depressive disorder influences intent to die in violent suicide attempters. Astruc, May 690–695
Lack of association between plasma apolipoprotein E and suicide attempts [letter]. Baca-Garcia, Apr 580–581
Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. Leon, July 915–918
Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. Glick, May 679–685
Psychopathology of seasonal affective disorder patients in comparison with major depression patients who have attempted suicide. Pendse, Mar 322–327
Relapse in pedophilic sex offending and subsequent suicide attempt during luteinizing hormone–releasing hormone treatment [ietter]. Briken, Oct 1429
Suicidality as a possible side effect of antidepressant treatment [commentary]. Culpepper, June 742–749
Suicide attempts and ideation in patients with bipolar I disorder. Fagiolini, Apr 509–514
Sydenham's Chorea
Obsessive-compulsive spectrum disorders in rheumatic fever with and without Sydenham's chorea. Hounie, July 994–999
Tardive Dyskinesia
Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. Richardson, Jan 92–96
New nomenclature for drug-induced movement disorders including tardive dyskinesia. Chouinard, Suppl 9, 9–15
Single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Emsley, May 696–701
Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. Kane, Suppl 9, 16–20
Tardive dyskinesia rates with atypical antipsychotics in older adults. Jeste, Suppl 9, 21–24
Tardive Dystonia
Case of tardive dystonia successfully managed with quetiapine [letter]. Sasaki, Apr 583–584
Texas Medication Algorithm Project
Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Miller, Apr 500–508
Thromboembolism
Case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics [letter]. Toki, Nov 1576–157
Tic Disorder
Association of small life events with self reports of tic severity in pediatric and adult tic disorder patients: a prospective longitudinal study. Hoekstra, Mar 426–431
Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. Hoekstra, Apr 537–542
Topiramate
Open trial of topiramate in the treatment of generalized social phobia. Van Ameringen, Dec 1674–1678
Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? [letter] Duggal; Hofer reply, Aug 1145–1146
Topiramate in the long-term treatment of binge-eating disorder associated with obesity. McElroy, Nov 1463–1469
Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. Nickel, Nov 1515–1519
Transcranial Magnetic Stimulation
Can bilateral prefrontal repetitive transcranial magnetic stimulation (rTMS) induce mania? a case report [letter]. Hausmann, Nov 1575–1576
No deterioration of cognitive performance in an aggressive unilateral and bilateral antidepressant rTMS add-on trial. Hausmann, June 772–782
3-Month, follow-up, randomized, placebo-controlled study of repetitive transcranial magnetic stimulation in depression. Koerselman, Oct 1323–1328
Tranylcypromine
Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. Birkenhäger, Nov 1505–1510
Trazodone
Use of trazodone as a hypnotic: a critical review. James, June 752–755
Trichotillomania
Alternative pharmacotherapy for trichotillomania: a report of successful bupropion use [letter]. Bhanji, 1283
United States
Antidepressants and suicide risk in the United States, 1985–1999. Grunebaum, Nov 1456–1462
Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. Calabrese, Nov 1499–1504
National trends in the outpatient treatment of anxiety disorders. Olfson, Sept 1166–1173
Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Ganguly, Oct 1377–1388
Urination
Venlafaxine-induced increase in urinary frequency in 3 women [letter]. Hansen, June 877–878
Valproate
Dosing differences between valproic acid concentrate and divalproex sodium: a case report [letter]. Coffey, May 724–725
Single-dose intravenous valproate in acute mania. Phrolov, Jan 68–70
Valproate for hostility in schizophrenia patients [letter]. Littrell, Jan 134
Venlafaxine
Double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Bielski, Sept 1190–1196
Double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. Denys, Jan 37–43
Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder. Lydiard, June 838–844
Possible case of venlafaxine-induced Stevens-Johnson syndrome [letter]. Weiss NT, Oct 1431–1433
Venlafaxine-induced increase in urinary frequency in 3 women [letter]. Hansen, June 877–878
Venlafaxine versus placebo in the preventive treatment of recurrent major depression. Montgomery, Mar 328–336
Venlafaxine XR and chronic pelvic pain syndrome [letter]. Karp, June 880–881
Withdrawal reactions associated with low-dose venlafaxine treatment in a patient with premenstrual dysphoric disorder [letter]. Hsiao, Aug 1147–1148
Violence
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. Swanson, Dec 1666–1673
Visual Hallucinations
Visual hallucinations with sertraline [letter]. Marcon, Mar 446–447

Vitamin B_6
Vitamin B_6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. Lerner, Nov 1550–1554
Vitamin B_{12}
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. Papakostas, Aug 1090–1095
Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. Papakostas, Aug 1096–1098
Weight
Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Lu M-L, June 766–771
Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. Suppl 7, 1–20
Are mood disorders and obesity related? a review for the mental health professional. McElroy, May 634–651
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Lee E, June 864–866
Comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. McQuade, Suppl 18, 47–56
Consensus development conference on antipsychotic drugs and obesity and diabetes. Feb 267–272
Development of guidelines for preventing and managing obesity and diabetes in mentally ill patients [letter]. Gupta S, Aug 1149
Managing atypical antipsychotic–associated weight gain: 12-month data on a multimodal weight control program. Menza, Apr 471–477
Schizophrenia and obesity: impact of antipsychotic medications. Wirshing, Suppl 18, 13–26
Topiramate in the long-term treatment of binge-eating disorder associated with obesity. McElroy, Nov 1463–1469
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. Maina, Oct 1365–1371
Weight gain during treatment of bipolar I patients with olanzapine. Hennen, Dec 1679–1687
Women
Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. Berle, Sept 1228–1234
Bupropion and breastfeeding: a case of a possible infant seizure [letter]. Chaudron, June 881–882
Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Philipsen, Oct 1414–1419
Focus on women's mental health [editorial]. Freeman MP, Sept 1164–1165
In the puerperium, primiparae exhibit higher levels of anxiety and serum peptidase activity and greater immune responses than multiparae. Maes, Jan 71–76
Introduction: postpartum depression. Freeman MP, Sept 1235
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Oberlander, Feb 230–237
Postpartum depression recurrence versus discontinuation syndrome: observations from a randomized controlled trial. Sunder, Sept 1266–1268
Preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Zanarini, July 903–907
Preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Reich, Dec 1601–1606
Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. Epperson, Mar 421–425
Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. Perkonigg, Oct 1314–1322
Serotonin function, personality-trait variations, and childhood abuse in women with bulimia-spectrum eating disorders. Steiger, June 830–837
Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. Nickel, Nov 1515–1519
Treatment of postpartum depression, part 1: a critical review of biological interventions. Dennis, Sept 1242–1251
Treatment of postpartum depression, part 2: a critical review of nonbiological interventions. Dennis, Sept 1252–1265
Use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. Misri, Sept 1236–1241
Venlafaxine-induced increase in urinary frequency in 3 women [letter]. Hansen, June 877–878
Ziprasidone
Effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Barbee, July 975–981
Effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. Cohen, Jan 110–113
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Addington, Dec 1624–1633
Hypomanic episodes after receiving ziprasidone: an unintended "on-off-on" course of treatment [letter]. Brieger, Jan 132
Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report [letter]. Anghelescu, Sept 1286–1287
Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. Papakostas, Feb 217–221
Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services [letter]. Pascual, Sept 1281–1283
Zolpidem
Case of parenteral zolpidem dependence with opioid-like withdrawal symptoms [letter]. Kao, Sept 1287
Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. Perlis, Aug 1128–1137
Zonisamide
Cautionary note when using zonisamide in youths: a case report of association with toxic epidermal necrolysis [letter]. Majeres, Dec 1720
Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. McElroy, Jan 50–56

The Journal of Clinical Psychiatry

Author Index to Volume 65: January 2004 Through December 2004

Aamo TO see Berle JØ

Aboujaoude E, Gamel N, Koran LM. Case of kleptomania correlating with premenstrual dysphoria [letter]. May 725–726

Abrams M see Krell HV

Achenbach S see Barbarich NC

Ackerman DL see Bystritsky A

Adams BE see Khan A

Addington DEN, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Dec 1624–1633

Adler LA. Clinical presentations of adult patients with ADHD. Suppl 3, 8–11

Adler LA see Murphy KR

Akers RF see Glazer WM

Albano D see Zajecka JM

Alber RC see Pomerantz JM

Albert U see Maina G

Alexopoulos GS, Streim J, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Using Antipsychotic Agents in Older Patients. Suppl 2, 1–105

Alkın T see Bandelow B

Allen AJ see Slattery MJ

Alméras N, Després J-P, Villeneuve J, Demers M-F, Roy M-A, Cadrin C, Mottard J-P, Bouchard R-H. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. Apr 557–564

Alpert JE, Franznick DA, Hollander SB, Fava M. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Aug 1069–1075

Alpert JE see Papakostas GI

Altshuler LL see State RC; Quanbeck CD

Alvarez E see Pascual JC

Aman MG, Gharabawi GM, for the Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Sept 1197–1210

Amiel SA see Howes OD

Amo C, Quesney LF, Ortiz T, Maestú F, Fernández A, López-Ibor MI, López-Ibor JJ. Limbic paroxysmal magnetoencephalographic activity in 12 obsessive-compulsive disorder patients: a new diagnostic finding. Feb 156–162

Anand A see Perry EB Jr

Ananth J, Johnson KM, Levander EM, Harry JL. Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate [letter]. May 724

Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. Apr 464–470

Ancoli-Israel S see Benca RM

Andrade C. Antidepressant-withdrawal mania: a critical review and synthesis of the literature. July 987–993

Andrade C. Possible impact of dropout in a study of high-dose olanzapine and prolactin levels [letter with reply]. Aug 1150

Andreasen RG. Review of Spitzer RL, First MB, Gibbon M, Williams JBW (eds): *Treatment Companion to the DSM-IV-TR Casebook.* Oct 1435–1436

Andreasen RG. Review of Stern TA, Herman JB: *Massachusetts General Hospital 1000 Psychiatry Questions & Annotated Answers.* Sept 1288–1289

Andreasen RG. Review of Stern TA, Herman JB (eds): *Massachusetts General Hospital Psychiatry Update and Board Preparation, Second Edition.* Sept 1288–1289

Andreoli A see Damsa C

Angelone SM see Cavallaro R

Anghelescu I, Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report [letter]. Sept 1286–1287

Anghelescu I see Wetzel H

Anthony M see Freeman MP

Aouillé J see Esposito D

Applebaum J see Phrolov K

Archibald D see McQuade RD

Arnold DS, Rosse RB, Dickinson D, Benham R, Deutsch SI, Nelson MW. Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient [letter]. Dec 1723–1724

Arnold LM see McElroy SL

Arnow BA. Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization. Suppl 12, 10–15

Arolt V see Michael N

Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM, Navarro MA, San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. Oct 1335–1342

Ascher J see McElroy SL

Aslan M see Batten SV

Asnis GM, De La Garza R II, Miller AH, Raison CL. Ribavirin may be an important factor in IFN-induced neuropsychiatric effects [letter with reply]. Apr 581

Asnis GM see Khan A

Astruc B, Torres S, Jollant F, Jean-Baptiste S, Castelnau D, Malafosse A, Courtet P. History of major depressive disorder influences intent to die in violent suicide attempters. May 690–695

Atbasoglu EC, Ozguven HD, Saka MC, Goker C. Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome [letter]. Dec 1724–1725

Aubry J-M see Rachid F

Aviv A, Shelef A, Weizman A. Open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. Jan 97–103

Axelson D see Yorbik O

Azhar N see Schwartz TL

Baca-Garcia E, Diaz-Sastre C, García-Resa E, Ceverino A, Ramirez A, Saiz-Ruiz J, de Leon J. Lack of association between plasma apolipoprotein E and suicide attempts [letter]. Apr 580–581

Baeza I see Parellada E

Bailey D see Le Mellédo J-M

Bailine SH see Husain MM

Baksh A see Karagianis JL

Baldassano CF see Hahn C-G

Baldessarini RJ see Hennen J; Vieta E

Balestrieri M see Marcon G

Ballard CG, Margallo-Lana ML. Relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. Suppl 11, 23–28

Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, Bannister C, McShane R, Swann A, Juszczak E, O'Brien JT. 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory median cutoff is a predictor of clinical outcome. Jan 114–119

Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. Dec 1696–1707

Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, International Consensus Group on Depression and Anxiety. Introduction: update on posttraumatic stress disorder. Suppl 1, 3

Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Marshall RD, Nemeroff CB, Shalev AY, Yehuda R. Consensus statement update on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. Suppl 1, 55–62
Balon R. Financial support for letter writing? [letter] May 721
Banac S see Frodl T
Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkın T, Goebel C, Clary CM. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. Mar 405–413
Banerji MA see Casey DE
Bannister C see Ballard CG
Baran AS see Rack MJ
Barbarich NC, McConaha CW, Gaskill J, La Via M, Frank GJ, Achenbach S, Plotnicov KH, Kaye WH. Open trial of olanzapine in anorexia nervosa. Nov 1480–1482
Barbe RP, Bridge JA, Birmaher B, Kolko DJ, Brent DA. Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. Jan 77–83
Barbee JG, Conrad EJ, Jamhour NJ. Effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. July 975–981
Barkenbus JE see Corson AH
Barrachina J see Pascual JC
Barrett EJ see Kane JM
Basinski J see Whyte EM
Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. Suppl 11, 16–22
Bastean JN see Mulsant BH
Batten SV, Aslan M, Maciejewski PK, Mazure CM. Childhood maltreatment as a risk factor for adult cardiovascular disease and depression. Feb 249–254
Beckman D see Dunsieth NW Jr
Beesdo K see Bittner A
Begin A see Simpson EB
Begin H see Boylan KR
Begley A see Whyte EM
Behnke K see Bandelow B
Bellino S, Rocca P, Patria L, Marchiaro L, Rasetti R, Di Lorenzo R, Paradiso E, Bogetto F. Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. July 908–914
Bellivier F see Slama F
Belmaker R H see Phrolov K
Benattia I see Addington DEN
Benazzi F. Anger in depressive mixed states [letter with reply]. Nov 1578–1579
Benca RM, Ancoli-Israel S, Moldofsky H. Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. Suppl 8, 26–35
Bender DS see Gunderson JG
Benham R see Arnold DS
Bennett M see Van Ameringen M
Bergant A see Rettenbacher MA
Bergman J see Lerner V
Bergonzi P see Marcon G
Bergtholdt B see Lepola U
Berigan TR. Possible role of divalproex sodium in sedation induced by antipsychotic medications [letter with reply]. Jan 133
Berle JØ, Steen VM, Aamo TO, Breilid H, Zahlsen K, Spigset O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. Sept 1228–1234
Berman RM see Perry EB Jr
Bernardo M see Navarro V
Berndt E see Pomerantz JM; Russell JM
Berner W see Briken P
Bernstein HJ see Husain MM
Berrettini WH see Bulik CM
Berry SA see Lindenmayer J-P
Bertschy G see Rachid F
Beyenburg S see Damsa C
Bhanji NH, Margolese HC. Alternative pharmacotherapy for trichotillomania: a report of successful bupropion use [letter]. 1283
Bianchi-Demicheli F see Damsa C
Biancosino B see Grassi L
Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. Suppl 3, 3–7
Bieling PJ see Boylan KR
Bielski RJ, Ventura D, Chang C-C. Double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Sept 1190–1196
Biggs MM see Husain MM
Biondi M see Picardi A
Birkenhäger TK, Renes J-W, Pluijms EM. One-year follow-up after successful ECT: a naturalistic study in depressed inpatients. Jan 87–91
Birkenhäger TK, van den Broek WW, Mulder PG, Bruijn JA, Moleman P. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. Nov 1505–1510
Birmaher B see Barbe RP; Yorbik O
Bitter I see Dossenbach M
Bittner A, Goodwin RD, Wittchen H-U, Beesdo K, Höfler M, Lieb R. What characteristics of primary anxiety disorders predict subsequent major depressive disorder? May 618–626
Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. Jan 104–109
Bogetto F see Bellino S; Maina G
Bohrer E see Niedermaier N
Bohus M see Philipsen A
Boland J see Dossenbach M
Bondolfi G see Rachid F
Bose A see Rapaport MH
Bosmans E see Maes M
Boss DT see Pomerantz JM
Bossie CA see Currier GW; Mulsant BH
Botha K see Emsley R
Bottiglieri T see Papakostas GI
Bottlender R see Frodl T
Botts S, Littrell R, de Leon J. Variables associated with high olanzapine dosing in a state hospital. Aug 1138–1143
Botts S see Coffey G
Bouchard R-H see Alméras N
Bowden CL. Introduction: managing bipolar depression. Suppl 10, 3–4
Bowden CL. Making optimal use of combination pharmacotherapy in bipolar disorder. Suppl 15, 21–24
Bowden CL, Myers JE, Grossman F, Xie Y. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. May 707–714
Bowden CL see Goodwin GM
Bowers MB Jr see Lim S
Boylan KR, Bieling PJ, Marriott M, Begin H, Young LT, MacQueen GM. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. Aug 1106–1113
Breilid H see Berle JØ
Bremner JD, Mletzko T, Welter S, Siddiq S, Reed L, Williams C, Heim CM, Nemeroff CB. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. Nov 1559–1564
Brent DA see Barbe RP
Bridge JA see Barbe RP
Brieger P. Hypomanic episodes after receiving ziprasidone: an unintended "on-off-on" course of treatment [letter]. Jan 132
Briken P, Hill A, Berner W. Relapse in pedophilic sex offending and subsequent suicide attempt during luteinizing hormone–releasing hormone treatment [letter]. Oct 1429
Brodaty H see Rabinowitz J
Brotto SA see Diniz JB
Brown FW. Review of Agronin ME: *Dementia: A Practical Guide*. June 884
Brugger A see Rettenbacher MA
Bruijn JA see Birkenhäger TK
Brunette MF see Clark RE
Bruscoli M see Pallanti S
Brusman-Lovins LA see Dunsieth NW Jr
Buchanan RW see Miller AL
Buckley PF see Miller AL
Buffenstein A. Review of Leo RJ: *Concise Guide to Pain Management for Psychiatrists*. Apr 585
Bulik CM, Klump KL, Thornton L, Kaplan AS, Devlin B, Fichter MM, Halmi KA, Strober M, Woodside DB, Crow S, Mitchell JE, Rotondo A, Mauri M, Cassano GB, Keel PK, Berrettini WH, Kaye WH. Alcohol use disorder comorbidity in eating disorders: a multicenter study. July 1000–1006
Bull SA see Hu XH
Bumb A see Damsa C
Burgoyne K see Ananth J
Burke WJ. Selective versus multi-transmitter antidepressants: are two mechanisms better than one? Suppl 4, 37–45
Burt VK. Plotting the course to remission: the search for better outcomes in the treatment of depression. Suppl 12, 20–25
Bushey MP see Lamberti JS
Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Apr 565–568

Cadrin C see Alméras N
Calabrese JR, Hirschfeld RMA, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. Nov 1499–1504
Calabrese JR see Goodwin GM; Hirschfeld RMA; Swann AC; Vieta E
Cancelli I see Marcon G
Cao LY see Zhang XY
Capece JA see McElroy SL
Carfagno ML see Trivedi MH
Caro JJ. Reply to Compton MT: Potential for detection bias in the association between olanzapine and diabetes [letter]. Feb 275
Carpenter D see Alexopoulos GS
Carroll BT, Lee JWY. Catatonia is a risk factor for neuroleptic malignant syndrome [letter]. Dec 1722–1723
Carson WH see McQuade RD
Casey DE. Dyslipidemia and atypical antipsychotic drugs. Suppl 18, 27–35
Casey DE. Pathophysiology of antipsychotic drug–induced movement disorders. Suppl 9, 25–28
Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer J-P, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH. Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. Suppl 7, 1–20
Casey DE see Kane JM
Caspi A see Weiser M
Cassano GB see Bulik CM
Castelnau D see Astruc B
Catena M see Ramacciotti CE
Cather C see Evins AE; Freudenreich O
Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. Feb 187–190
Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Reply to Rack MJ: Cardiopulmonary complications of ergot-derivative dopamine agonists [letter]. Oct 1430
Ceverino A see Baca-Garcia E
Chaitin BF. Review of Leahy RL: *Cognitive Therapy Techniques: A Practitioner's Guide*. Nov 1581
Chakos M see Lindenmayer J-P
Chamberlain JC see Weiss NT
Chan YK see Sim K
Chang C-C see Bielski RJ
Chang KD see Post RM
Chang W-H see Lu M-L
Chao HM see Richardson MA
Charney DS see Perry EB Jr
Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of a possible infant seizure [letter]. June 881–882
Chelminski I see Zimmerman M
Chen K-P see Lu M-L
Chengappa KNR see Mammen OK
Chiles JA see Miller AL
Chinman M, Young AS, Schell T, Hassell J, Mintz J. Computer-assisted self-assessment in persons with severe mental illness. Oct 1343–1351
Chong PN see Sim K
Chou JC-Y see Currier GW
Chou SP see Grant BF
Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. Suppl 5, 7–12
Chouinard G. New nomenclature for drug-induced movement disorders including tardive dyskinesia. Suppl 9, 9–15
Ciapparelli A see Ramacciotti CE
Citrome L see Lindenmayer J-P; Volavka J
Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. Feb 151–155
Clark RE, Xie H, Brunette MF. Reply to Lieberman DZ: Prescribing benzodiazepines for patients with substance use disorders [letter]. Nov 1577–1578
Clary CM see Bandelow B
Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. Placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor–induced sexual dysfunction. Jan 62–67
Clelland JD see Richardson MA
Coccaro EF, Schmidt CA, Samuels JF, Nestadt G. Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. June 820–824
Cocchi F see Cavallaro R
Coffey G, Botts S, de Leon J. Dosing differences between valproic acid concentrate and divalproex sodium: a case report [letter]. May 724–725
Cohen D see Spoelstra JA
Cohen SA, Fitzgerald BJ, Khan SRF, Khan A. Effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. Jan 110–113
Cole K see Schwartz TL
Colom F see Vieta E
Compton MT, Hill HA. Potential for detection bias in the association between olanzapine and diabetes [letter with reply]. Feb 274
Conca A see Hausmann A
Conley RR see Miller AL
Conrad EJ see Barbee JG
Cook IA see Krell HV
Cookson J see McElroy SL
Coomaraswamy S see Raby WN
Cooper C see Lim S
Cooper TB see Lindenmayer J-P; Volavka J
Corral M see Misri S
Correll CU see Kane JM
Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. Retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. Nov 1531–1536
Costea GO see Lamberti JS
Costello E see Simpson EB
Courtet P see Astruc B
Crilly JF see Lamberti JS
Crismon ML see Miller AL
Crits-Christoph P see Gelenberg AJ
Crow S see Bulik CM
Crown WH see Russell JM
Crystal S see Walkup JT
Culpepper L. Identifying and treating panic disorder in primary care. Suppl 5, 19–23
Culpepper L. Medicine: the coming challenges and opportunities [editorial]. June 740–741
Culpepper L, Davidson JRT, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL. Suicidality as a possible side effect of antidepressant treatment [commentary]. June 742–749
Cúri M see Diniz JB; Hounie AG
Curkendall SM, Mo J, Glasser DB, Stang MR, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. May 715–720
Currier GW, Chou J C-Y, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi GM. Acute treatment of agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Mar 386–394
Czobor P see Lindenmayer J-P; Volavka J
Daley TB see Henderson DC
Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, Beyenburg S. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. Aug 1064–1068
Daniel DG see Swann AC
Dar R see Hermesh H
Das M see Pomerantz JM
Daversa MT see Gunderson JG
Davidson JRT. Long-term treatment and prevention of posttraumatic stress disorder. Suppl 1, 44–48
Davidson JRT. Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. Suppl 5, 29–33
Davidson JRT see Ballenger JC; Culpepper L
Davidson M see Casey DE; Rabinowitz J; Weiser M
Davies MA see Hirschfeld RMA
Davis KH see Khan A
Davy KL see Lepola U
Dawson DA see Grant BF
de Alvarenga PG see Hounie AG
DeAntonio M see State RC
De Deyn PP see Rabinowitz J
de Geus F see Denys D
De La Garza R II see Asnis GM
DelBello M, Grcevich S. Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. Suppl 6, 12–19
de Leon J. Respiratory infections rather than antibiotics may increase clozapine levels: a critical review of the literature [letter]. Aug 1144–1145
de Leon J see Baca-Garcia E; Botts S; Coffey G
Delespaul PAEG see Myin-Germeys I
Delgado PL. Common pathways of depression and pain. Suppl 12, 16–20
Delgado PL. How antidepressants help depression: mechanisms of action and clinical response. Suppl 4, 25–30
Dell'Osso L see Ramacciotti CE
del Pilar Castillo Abadia M see Le Mellédo J-M
de Mathis MA see Hounie AG
Demers M-F see Alméras N

Dennehy EB, Gonzalez R, Suppes T. Self-reported participation in nonpharmacologic treatments for bipolar disorder [letter]. Feb 278
Dennis C-LE. Treatment of postpartum depression, part 2: a critical review of nonbiological interventions. Sept 1252–1265
Dennis C-LE, Stewart DE. Treatment of postpartum depression, part 1: a critical review of biological interventions. Sept 1242–1251
Denys D, de Geus F, van Megen HJGM, Westenberg HGM. Double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Aug 1040–1048
Denys D, van Megen HJGM, van der Wee N, Westenberg HGM. Double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. Jan 37–43
Denys D, Zohar J, Westenberg HGM. Role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. Suppl 14, 11–17
de Pablo J see Parellada E
DeQuardo JR. Modafinil and antipsychotic-induced sedation [letter with reply]. Feb 278–279
DeQuardo JR. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? [letter] Jan 132–133
Després J-P see Alméras N
Detke MJ see Fava M
Deutsch SI see Arnold DS
Devlin B see Bulik CM
Dew MA see Whyte EM
Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. Mar 354–360
Diaz-Sastre C see Baca-Garcia E
Dickinson D see Arnold DS
Diefenbach GJ see Tolin DF
Dietrich AJ see Culpepper L
Dietz MB see Lamberti JS
Dillingham KE see Trivedi MH
Di Lorenzo R see Bellino S
Dineen M see Addington DEN
Diniz JB, Rosario-Campos MC, Shavitt RG, Curi M, Hounie AG, Brotto SA, Miguel EC. Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. Jan 22–27
Docherty JP see Alexopoulos GS
Dodson W see Wilens TE
Doghramji K. Assessment of excessive sleepiness and insomnia as they relate to circadian rhythm sleep disorders. Suppl 16, 17–22
Doghramji PP. Recognizing sleep disorders in a primary care setting. Suppl 16, 23–26
Doraiswamy PM see Koller EA
Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, for the IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Mar 312–321
Doyle A, Pollack MH. Long-term management of panic disorder. Suppl 5, 24–28
Doyle AC see Simon NM
Dubbert BK see Slattery MJ
Duchesne I see Nasrallah HA
Dueñas R see Arranz B
Duggal HS. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? [letter with reply] Aug 1145
Duggal HS, Gandotra G. Comments on cost analysis of risperidone versus olanzapine [letter with reply]. June 879–880
Dunner DL. Correlates of suicidal behavior and lithium treatment in bipolar disorder. Suppl 10, 5–10
Dunner DL. Review of Abrams R: *Electroconvulsive Therapy, 4th ed.* Feb 280
Dunner DL. Review of Potokar J, Thase ME (eds): *Advances in the Management and Treatment of Depression.* May 729
Dunner DL see Gelenberg AJ
Dunsieth NW Jr, Nelson EB, Brusman-Lovins LA, Holcomb JL, Beckman D, Welge JA, Roby D, Taylor P Jr, Soutullo CA, McElroy SL. Psychiatric and legal features of 113 men convicted of sexual offenses. Mar 293–300
Dvorin S see Lamberti JS
Ebert TH see Pomerantz JM
Eder U see Hofer A; Rettenbacher MA
Edinger JD. Classifying insomnia in a clinically useful way. Suppl 8, 36–43
Edlinger M see Hofer A
Eerdekens E see Lindenmayer J-P
Eerdekens M see Lindenmayer J-P; Nasrallah HA
Ekstrom RD see Nicholas LM
Elbogen EB see Swanson JW
Ellis SP see Grunebaum MF
el Mahfoud Kessaci M see Dossenbach M
Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. Single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. May 696–701
Engström G see Pendse BPG
Entsuah R see Montgomery SA
Epperson CN, Terman M, Terman JS, Hanusa BH, Oren DA, Peindl KS, Wisner KL. Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. Mar 421–425
Epstein LC. Review of Kornstein SG, Clayton AH (eds): *Women's Mental Health: A Comprehensive Textbook.* Mar 448–449
Ereshefsky L see Miller AL
Erfurth A see Michael N
Erkens JA see Spoelstra JA
Erol A see Dossenbach M
Escalona R see Lu BY
Esposito D, Aouillé J, Rouillon F, Limosin F. Two-year follow-up of a patient with successful continuation of clozapine treatment despite morning pseudoneutropenia [letter]. Sept 1281
Esposito SM see Nicholas LM
Essock SM see Miller AL
Etain B see Slama F
Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, Goff DC. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. Mar 307–311
Evins AE see Freudenreich O
Fagiolini A, Kupfer DJ, Rucci P, Scott JA, Novick DM, Frank E. Suicide attempts and ideation in patients with bipolar I disorder. Apr 509–514
Fang M see Samuels S
Farhi P see Whyte EM
Fava M. Daytime sleepiness and insomnia as correlates of depression. Suppl 16, 27–32
Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. Effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? Apr 521–530
Fava M see Alpert JE; Joliat MJ; Papakostas GI
Fazzio L see McElroy SL
Feifel D see Currier GW
Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. Nov 1520–1524
Feldmann TB. Review of Volavka J: *Neurobiology of Violence, Second Edition.* May 727
Fernández A see Amo C
Fernández P see Arranz B
Ferrando SJ see Rabkin JG
Fichter MM see Bulik CM
Findling RL. Introduction: atypical antipsychotics in the treatment of children and adolescents. Suppl 6, 3–4
Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. Suppl 6, 30–44
Findling RL see Post RM
Fink M see Husain MM
Finkelstein S see Pomerantz JM; Russell JM
Finlayson AJR. Review of Abrams DB, Niaura R, Brown RA, Emmons KM, Goldstein MG, Monti PM: *The Tobacco Dependence Treatment Handbook: A Guide to Best Practices.* May 727–728
Finnerty M see Miller AL
Fireman B see Hu XH
Fischmann D see Simon NM
Fitzgerald BJ see Cohen SA
Fitzgerald CE see Oberlander TF
Fitzgerald RG. Review of Robinson DJ: *Reel Psychiatry: Movie Portrayals of Psychiatric Conditions.* Aug 1152
Fleischhacker WW see Hofer A; Rettenbacher MA
Fogh K see Nielsen JN
Ford AL see Nicholas LM
Ford CV. Review of McNally RJ: *Remembering Trauma.* Nov 1580
Fossey J see Ballard CG
Frank BL see Gupta S
Frank E see Fagiolini A
Frank GJ see Barbarich NC

Frankenburg FR, Zanarini MC. Association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. Dec 1660–1665
Frankenburg FR see Zanarini MC
Franznick DA see Alpert JE
Freeman AM III. Review of Favazza A: *PsychoBible: Behavior, Religion and the Holy Book*. July 1022–1023
Freeman MP. Introduction: postpartum depression. Sept 1235
Freeman MP, Anthony M. Focus on women's mental health [editorial]. Sept 1164–1165
Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. Oct 1372–1376
Freudenreich O see Evins AE
Friedman JH. Historical perspective on movement disorders. Suppl 9, 3–8
Frodl T, Meisenzahl EM, Zetzsche T, Höhne T, Banac S, Schorr C, Jäger M, Leinsinger G, Bottlender R, Reiser M, Möller HJ. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. Apr 492–499
Frye MA see Hirschfeld RMA; Quanbeck CD; State RC
Frye MA see Calabrese JR
Fujii Y see Misawa F
Fukuda M see Misawa F
Fulmer J see Montgomery J
Gaebel W see Weinmann S
Gaetano P see Picardi A
Galea S see Marshall RD
Gallop RJ see Gelenberg AJ
Gamel N see Aboujaoude E
Gandotra G see Duggal HS
Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Oct 1377–1388
Gara M see Menza M
García-Resa E see Baca-Garcia E
Garfinkel PE see Ramacciotti CE
Gaskill J see Barbarich NC
Gastó C see Navarro V
Gaughran FP see Howes OD
Gauvin L see Steiger H
Geissler EC see Olfson M
Gelenberg AJ. Honoring our evidence base [commentary]. June 750–751
Gelenberg AJ. The *Journal* in 2004 [editorial]. Dec 1593–1596
Gelenberg AJ. Our reviewers [editorial]. Jan 4–7
Gelenberg AJ, Shelton RC, Crits-Christoph P, Keller MB, Dunner DL, Hirschfeld RMA, Thase ME, Russell JM, Lydiard RB, Gallop RJ, Todd L, Hellerstein DJ, Goodnick PJ, Keitner GI, Stahl SM, Halbreich U, Hopkins HS. Effectiveness of St. John's wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. Aug 1114–1119
Gelenberg AJ see Kane JM
Geller B see Post RM
Ghaemi SN, Pardo TB, Hsu DJ. Strategies for preventing the recurrence of bipolar disorder. Suppl 10, 16–23
Gharabawi GM see Aman MG; Currier GW; Mulsant BH
Gharbia NA see McQuade RD
Ginsberg LD see Khan A
Glass SJ see Ninan PT
Glasser DB see Curkendall SM
Glazer WM, Sonnenberg JG, Reinstein MJ, Akers RF. Novel, point-of-care test for lithium levels: description and reliability. May 652–655
Glick ID, Zaninelli R, Hsu C, Young FK, Weiss L, Gunay I, and Kumar V. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. May 679–685
Goebel C see Bandelow B
Goff DC see Evins AE; Freudenreich O
Goker C see Atbasoglu EC
Golden RN see Nicholas LM
Gonzales JS see Wohlreich MM
Gonzalez R see Dennehy EB
Goodman WK. Selecting pharmacotherapy for generalized anxiety disorder. Suppl 13, 8–13
Goodman WK see Culpepper L; Pallanti S
Goodnick PJ see Gelenberg AJ
Goodwin FK see Khan A
Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R. Pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Mar 432–441
Goodwin RD see Bittner A
Gorbis E see Bystritsky A
Gould TD, Manji HK. Molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry [editorial]. May 598–604
Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. Jan 10–21
Gourley MF see Slattery MJ
Grant BF, Hasin DS, Stinson FS, Dawson DA, Chou SP, Ruan WJ, Pickering RP. Prevalence, correlates, and disability of personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. July 948–958
Grassi L, Biancosino B, Marmai L, Righi R. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. Apr 515–520
Grcevich S see DelBello M
Green CH see Papakostas GI
Green MF see Harvey PD
Greene P see Goodwin GM; McElroy SL
Greenspan A see Rabinowitz J
Greenspan AJ see Mulsant BH
Greil W see Kleindienst N
Grilo CM see Gunderson JG
Grobbee DE see Spoelstra JA
Gross-Isseroff R see Hermesh H
Grossman F see Bowden CL
Grunebaum MF, Ellis SP, Li S, Oquendo MA, and Mann JJ. Antidepressants and suicide risk in the United States, 1985–1999. Nov 1456–1462
Grunze H see Goodwin GM
Gunatilake S see Ananth J
Gunay I see Glick ID
Gunderson JG, Morey LC, Stout RL, Skodol AE, Shea MT, McGlashan TH, Zanarini MC, Grilo CM, Sanislow CA, Yen S, Daversa MT, Bender DS. Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. Aug 1049–1056
Gupta N, Mattoo SK. Reply to Mago R: Searching the medical literature for case reports [letter]. Mar 444–446
Gupta S, Frank BL. Development of guidelines for preventing and managing obesity and diabetes in mentally ill patients [letter]. Aug 1149
Gyenes G see Le Mellédo J-M
Gyulai L see Hahn C-G
Hackett D see Lydiard RB; Montgomery SA
Hadar H see Shalev AY
Hahn C-G, Gyulai L, Baldassano CF, Lenox RH. Current understanding of lamotrigine as a mood stabilizer. June 791–804
Haker H see Jung HH
Halbreich U see Gelenberg AJ
Hall CS see Miller AL
Halmi KA see Bulik CM
Han X see Hudson TJ
Hannan SE see Tolin DF
Hansen LK. Venlafaxine-induced increase in urinary frequency in 3 women [letter]. June 877–878
Hanusa BH see Epperson CN; Sunder KR
Hapke U see John U
Harry JL see Ananth J
Harvey PD, Green MF, Keefe RSE, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Mar 361–372
Hasin DS see Grant BF
Hassell J see Chinman M
Hassman HA see Ninan PT
Haupt DW see Casey DE
Hausmann A, Kramer-Reinstadler K, Lechner-Schoner T, Walpoth M, Rupp CI, Hinterhuber H, Conca A. Can bilateral prefrontal repetitive transcranial magnetic stimulation (rTMS) induce mania? a case report [letter]. Nov 1575–1576
Hausmann A, Mangweth B, Walch T, Rupp CI, Pope HG Jr. Body-image dissatisfaction in gay versus heterosexual men: is there really a difference? Nov 1555–1558
Hausmann A, Pascual-Leone A, Kemmler G, Rupp CI, Lechner-Schoner T, Kramer-Reinstadler K, Walpoth M, Mechtcheriakov S, Conca A, Weiss EM. No deterioration of cognitive performance in an aggressive unilateral and bilateral antidepressant rTMS add-on trial. June 772–782
Hautzinger M see Wetzel H
Hawkins K see Russell JM
Hayden D see Henderson DC

Heiden A see Pjrek E
Heim CM see Bremner JD
Hellerstein DJ see Gelenberg AJ
Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. May 686–689
Henderson DC see Casey DE; Evins AE; Freudenreich O
Hendriks GJ see Bandelow B
Hennekens CH see Casey DE
Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ. Weight gain during treatment of bipolar I patients with olanzapine. Dec 1679–1687
Hennen J see Reich DB; Vieta E; Zanarini MC
Henry C see Slama F
Hermesh H, Konas S, Shiloh R, Dar R, Marom S, Weizman A, Gross-Isseroff R. Musical hallucinations: prevalence in psychotic and nonpsychotic outpatients. Feb 191–197
Heuser I see Niedermaier N
Hill A see Briken P
Hill HA see Compton MT
Hilligoss NM see Littrell KH
Hinterhuber H see Hausmann A
Hirschfeld RMA, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. Suppl 4, 46–52
Hirschfeld RMA, Vornik LA. Recognition and diagnosis of bipolar disorder. Suppl 15, 5–9
Hirschfeld RMA, Wagner KD, Holzer C, Calabrese JR, Davies MA, Weissman MM, Reed M, Frye MA, Keck PE Jr, McElroy SL, Lewis L, McNulty J. Response to commentary: Using questionnaires to screen for psychiatric disorders [letter]. May 721–722
Hirschfeld RMA see Calabrese JR; Gelenberg AJ
Hisatomi A see Kawashima T
Hodge A see Dossenbach M
Hoekstra PJ, Minderaa RB, Kallenberg CGM. Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. Apr 537–542
Hoekstra PJ, Steenhuis M-P, Kallenberg CGM, Minderaa RB. Association of small life events with self reports of tic severity in pediatric and adult tic disorder patients: a prospective longitudinal study. Mar 426–431
Hofer A, Fleischhacker WW, Hummer M. Reply to Duggal HS: Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? [letter] Aug 1145–1146
Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. July 932–939
Hofer A see Rettenbacher MA
Höfler M see Bittner A
Hoge EA see Simon NM
Höhne T see Frodl T
Holcomb JL see Dunsieth NW Jr
Hollander E, Zohar J. Introduction. Beyond refractory obsessions and anxiety states: toward remission. Suppl 14, 3–5
Hollander E see Pallanti S; Zohar J
Hollander SB see Alpert JE
Holzer C see Hirschfeld RMA
Hopkins G see Schwartz TL
Hopkins HS see Gelenberg AJ
Horn O see Werneke U
Hossie H see Lam RW
Hounie AG, Pauls DL, Mercadante MT, Rosário-Campos MC, Shavitt RG, de Mathis MA, de Alvarenga PG, Cúri M, Miguel EC. Obsessive-compulsive spectrum disorders in rheumatic fever with and without Sydenham's chorea. July 994–999
Hounie AG see Diniz JB
Howes OD, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. Effect of clozapine on factors controlling glucose homeostasis. Oct 1352–1355
Hsiao M-C, Liu C-Y. Withdrawal reactions associated with low-dose venlafaxine treatment in a patient with premenstrual dysphoric disorder [letter]. Aug 1147–1148
Hsu C see Glick ID
Hsu DJ see Ghaemi SN
Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. July 959–965
Huang S-C see Kao C-L
Hudson JI see McElroy SL
Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G. Pilot study of barriers to medication adherence in schizophrenia. Feb 211–216
Huffman RF see McElroy SL
Hummer M see Hofer A; Rettenbacher MA
Hunkeler EM see Hu XH
Husain J see Schwartz TL
Husain MM, Rush AJ, Fink M, Knapp R, Petrides G, Rummans T, Biggs MM, O'Connor K, Rasmussen K, Litle M, Zhao W, Bernstein HJ, Smith G, Mueller M, McClintock SM, Bailine SH, Kellner SH. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. Apr 485–491
Hwang S see State RC
Iancu I see Lepkifker E
IC-SOHO Study Group see Dossenbach M
International Consensus Group on Depression and Anxiety see Ballenger JC
Iosifescu DV see Papakostas GI
Ismail MS see Tariot PN
Isohanni M see Saari K
Isometsä ET see Melartin TK
Israël M see Steiger H
Jacoby R see Ballard CG
Jäger M see Frodl T
James SP, Mendelson WB. Use of trazodone as a hypnotic: a critical review. June 752–755
Jamhour NJ see Barbee JG
Janagap C see Nasrallah HA
Janssen B see Weinmann S
Jean-Baptiste S see Astruc B
Jefferson JW see Piasecki SD
Jessani M see Montgomery J
Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. Suppl 9, 21–24
Jimerson NA see Mittal D
Jody D see McQuade RD
John U, Meyer C, Rumpf H-J, Hapke U. Depressive disorders are related to nicotine dependence in the population but do not necessarily hamper smoking cessation. Feb 169–176
Johnson CG see Littrell KH
Johnson KM see Ananth J
Johnson WD see Mittal D
Jokelainen J see Saari K
Joliat MJ, Schmidt ME, Fava M, Zhang S, Michelson D, Trapp NJ, Miner CM. Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. Mar 373–378
Jollant F see Astruc B
Jones JK see Curkendall SM
Jones L see Weiss NT
Jones N see Schwartz TL
Joseph DI. Review of Pathé M: *Surviving Stalking*. Mar 449
Josiassen RC see Montgomery J
Jung HH, Haker H. Schizophrenia as a manifestation of X-linked McLeod-neuroacanthocytosis syndrome [letter]. May 722–723
Juszczak E see Ballard CG
Kadiyam V see Pomerantz JM
Kalali AH see Ketter TA; Weisler RH
Kallenberg CGM see Hoekstra PJ
Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. Suppl 9, 16–20
Kane JM, Barrett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, Newcomer JW. Metabolic effects of treatment with atypical antipsychotics [commentary]. Nov 1447–1455
Kao C-L, Huang S-C, Yang Y-J, Tsai S-J. Case of parenteral zolpidem dependence with opioid-like withdrawal symptoms [letter]. Sept 1287
Kaplan AS see Bulik CM
Karagianis JL, Baksh A. Reply to Andrade C: Possible impact of dropout in a study of high-dose olanzapine and prolactin levels [letter]. Aug 1150
Karp JF. Venlafaxine XR and chronic pelvic pain syndrome [letter]. June 880–881
Kasper S see Goodwin GM; Pjrek E
Katz IR see Rabinowitz J
Kawai M see Yokoshima T
Kawashima T, Oda M, Kuno T, Ueki H, Yamada S, Hisatomi A. Metyrapone for delirium due to Cushing's syndrome induced by occult ectopic adrenocorticotropic hormone secretion [letter]. July 1019–1020
Kaye WH see Barbarich NC; Bulik CM
Keck PE Jr. Defining and improving response to treatment in patients with bipolar disorder. Suppl 15, 25–29
Keck PE Jr. Evaluation and management of breakthrough depressive episodes. Suppl 10, 11–15
Keck PE Jr see Hirschfeld RMA; McElroy SL
Keefe RSE see Harvey PD
Keel PK see Bulik CM
Keitner GI see Gelenberg AJ
Keller MB. Improving the course of illness and promoting continuation of treatment of bipolar disorder. Suppl 15, 10–14

Keller MB. Remission versus response: the new gold standard of antidepressant care. Suppl 4, 53–59
Keller MB see Gelenberg AJ
Kellner SH see Husain MM
Kemmler G see Hausmann A; Hofer A; Rettenbacher MA
Kennedy JL see Zohar J
Kennedy K see Ganguly R
Kennedy RE see Mittal D
Kennedy S see Russell JM
Kessler MN. Possible effects of ibuprofen pretreatment on seizure duration during electroconvulsive therapy [letter]. Mar 442
Ketter TA, Kalali AM, Weisler RH, for the SPD417 Study Group. 6-Month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. May 668–673
Ketter TA see Weisler RH
Khan A, Ginsberg LD, Asnis GM, Goodwin FK, Davis KH, Krishnan AA, Adams BE. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. Nov 1483–1490
Khan A see Cohen SA
Khan SRF see Cohen SA
Kinrys G see Simon NM
Kirshner CD see Littrell KH
Kissling W see Leucht S
Klein S see Kane JM
Kleindienst N, Greil W. Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? July 966–974
Klibanski A see Misra M
Klump KL see Bulik CM
Klungel OH see Spoelstra JA
Knapp R see Husain MM
Knobler H see Weiser M
Knobler HY see Weiser M
Knüppel L, Linde K. Adverse effects of St. John's wort: a systematic review. Nov 1470–1479
Kochan LD see Swann AC
Koerselman F, Laman DM, van Duijn H, van Duijn MAJ, Willems MAM. 3-Month, follow-up, randomized, placebo-controlled study of repetitive transcranial magnetic stimulation in depression. Oct 1323–1328
Kohegyi E see Montgomery J
Koizumi T see Misawa F
Kolko DJ see Barbe RP
Koller EA, Weber J, Doraiswamy PM, Schneider BS. Survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. June 857–863
Konas S see Hermesh H
Konstantinidis A see Pjrek E
Koponen H see Saari K
Koran LM see Aboujaoude E; Zohar J
Kornstein SG see Clayton AH
Koshiishi F see Misawa F
Kostaras X see Oberlander TF
Kotler M see Lepkifker E
Kotwal R see McElroy SL
Kotzan JA see Ganguly R
Koul P see Henderson DC
Kowatch RA see Post RM
Koyama T see Sasaki Y
Krabbendam L see Myin-Germeys I
Kramer-Reinstadler K see Hausmann A
Kraus JE see Saik S
Kraus MR, Schäfer A. Reply to Asnis GM: Ribavirin may be an important factor in IFN-induced neuropsychiatric effects [letter]. Apr 581–582
Kravitz E see Weiser M
Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. Sept 1174–1179
Krem MM. Motor conversion disorders reviewed from a neuropsychiatric perspective. June 783–790
Krishnan AA see Khan A
Kroenke K see Culpepper L
Krystal AD. Changing perspective on chronic insomnia management. Suppl 8, 20–25
Krystal AD, Roth T. Introduction: definitions, measurements, and management in insomnia. Suppl 8, 5–7
Krystal AD see Perlis ML
Kumar V see Glick ID
Kunkel L see Henderson DC
Kuno T see Kawashima T
Kunz NR see Montgomery SA
Kupfer DJ see Fagiolini A; Mammen OK
Kusumi I see Sasaki Y
Kutcher SP see Post RM
Lahmann C see Nickel MK
Laitinen J see Saari K
Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. Mar 337–340
Laman DM see Koerselman F
Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, Costea GO, Bushey MP, Dietz MB. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. May 702–706
Lana MM see Ballard CG
Lane H-Y see Lu M-L
Lang AJ. Treating generalized anxiety disorder with cognitive-behavioral therapy. Suppl 13, 14–19
Lattuada E see Cavallaro R
Lauren L see Saari K
La Via M see Barbarich NC
Lawlor BA. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. Suppl 11, 5–10
Lawrence RW. Effect of mirtazapine versus fluoxetine on "sleep quality" [letter]. Aug 1149–1150
Leadbetter R see Goodwin GM
Lebovitz HE see Casey DE
Leboyer M see Slama F
Lechleitner M see Rettenbacher MA
Lechner-Schoner T see Hausmann A
Lecrubier Y. Posttraumatic stress disorder in primary care: a hidden diagnosis. Suppl 1, 49–54
Lecrubier Y see Ballenger JC
Lee E, Leung C-M, Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. June 864–866
Lee JWY see Carroll BT
Lee JY see Hu XH
Lee L see Ballard CG
Lee MA. Review of Cohen CI (ed): *Schizophrenia Into Later Life: Treatment, Research, and Policy*. May 729
Leiberich PK see Nickel MK
Leinsinger G see Frodl T
Le Mellédo J-M, del Pilar Castillo Abadia M, Newman S, Bailey D, Tsuyuki R, Gyenes G. Effects of newer antidepressants on low-density lipoprotein cholesterol levels [letter with reply]. July 1017–1018
Lenoir S see Bandelow B
Lenox RH see Hahn C-G
Leon AC. Are two antidepressant mechanisms better than one? issues in clinical trial design and analysis. Suppl 4, 31–36
Leon AC. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments. Nov 1511–1514
Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. July 915–918
Leonard HL see Slattery MJ
Lepkifker E, Sverdlik A, Iancu I, Ziv R, Segev S, Kotler M. Renal insufficiency in long-term lithium treatment. June 850–856
Lepola U, Bergtholdt B, St. Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Feb 222–229
Lerner V, Bergman J, Statsenko N, Miodownik C. Vitamin B_6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. Nov 1550–1554
Leskelä US see Melartin TK
Lestelä-Mielonen PS see Melartin TK
Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Feb 177–186
Leucht S see Sevy S
Leuchter AF see Krell HV
Leufkens HGM see Spoelstra JA
Leung C-M see Lee E
Levander EM see Ananth J
Leverich GS see Post RM
Levine J see Phrolov K
Lewis L see Hirschfeld RMA
Li S see Grunebaum MF
Licht RW see Nielsen JN
Lieb K see Philipsen A
Lieb R see Bittner A; Perkonigg A
Lieberman DZ. Prescribing benzodiazepines for patients with substance use disorders [letter with reply]. Nov 1577
Lieberman JA see Lindenmayer J-P; Volavka J
Lim S, Pralea C, Schnitt J, Bowers MB Jr, Cooper C. Possible increased efficacy of low-dose clozapine when combined with aripiprazole [letter]. Sept 1284–1285
Limosin F see Esposito D
Lin S-K see Lu M-L
Linde K see Knüppel L
Lindeman S see Saari K

Lindenmayer J-P. Measuring efficacy of polypharmacy in schizophrenic inpatients [letter with reply]. Aug 1148
Lindenmayer J-P, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. Apr 551–556
Lindenmayer J-P, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Aug 1084–1089
Lindenmayer J-P see Casey DE; Volavka J
Link N see Simon NM
Litle M see Husain MM
Littrell KH, Petty RG, Hilligoss NM, Kirshner CD, Johnson CG. Valproate for hostility in schizophrenia patients [letter]. Jan 134
Littrell R see Botts S
Liu C-Y see Hsiao M-C
Loew TH see Nickel MK
Lomax JW. Review of Ghaemi SN: *The Concepts of Psychiatry: A Pluralistic Approach to the Mind and Mental Issues*. Oct 1435
Lomeña F see Navarro V
López-Ibor JJ see Amo C
López-Ibor MI see Amo C
Lörch B see Wetzel H
Lu BY, Woofter C, Escalona R. Case of prolonged peyote-induced psychosis resolved by sleep [letter]. Oct 1433–1434
Lu M-L, Lane H-Y, Lin S-K, Chen K-P, Chang W-H. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. June 766–771
Lu M-L, Shen WW. Sleep-related eating disorder induced by risperidone [letter]. Feb 273–274
Lubin G see Weiser M
Lucki I, O'Leary OF. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. Suppl 4, 11–24
Lydiard RB, Pitrosky B, Hackett D, White C. Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder. June 838–844
Lydiard RB see Gelenberg AJ
Lynch-Colonese K see Perry EB Jr
Mace S see Taylor DM
Maciejewski PK see Batten SV
MacQueen GM see Boylan KR
Maes M, Bosmans E, Ombelet W. In the puerperium, primiparae exhibit higher levels of anxiety and serum peptidase activity and greater immune responses than multiparae. Jan 71–76
Maestú F see Amo C
Mago R. Searching the medical literature for case reports [letter with reply]. Mar 444–445
Maharaj K see Lamberti JS
Mahmoud RA see Currier GW
Maidment KM see Bystritsky A
Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. Oct 1365–1371
Majeres KD, Suppes T. Cautionary note when using zonisamide in youths: a case report of association with toxic epidermal necrolysis [letter]. Dec 1720
Makela EH. Reply to Berigan TR: Possible role of divalproex sodium in sedation induced by antipsychotic medications [letter]. Jan 133, reply Dec 1725
Makela EH. Reply to DeQuardo JR: Modafinil and antipsychotic-induced sedation [letter]. Feb 279
Malafosse A see Astruc B
Malhotra S see McElroy SL
Malizia AL see Nutt DJ
Mallinckrodt CH see Fava M
Maltby N see Tolin DF
Mammen OK, Pilkonis PA, Chengappa KNR, Kupfer DJ. Anger attacks in bipolar depression: predictors and response to citalopram added to mood stabilizers. May 627–633
Mammen OK, Pilkonis PA, Chengappa KNR, Kupfer DJ. Reply to Benazzi F: Anger in depressive mixed states [letter]. Nov 1579
Mancini C see Van Ameringen M
Mangweth B see Hausmann A
Manji HK see Gould TD
Mann JJ see Grunebaum MF
Mann SG see Saik S
Manoukian SV see Casey DE
Mao L see Mulsant BH
Marangell LB. Importance of subsyndromal symptoms in bipolar disorder. Suppl 10, 24–27
Marchiaro L see Bellino S
Marcon G, Cancelli I, Zamarian L, Bergonzi P, Balestrieri M. Visual hallucinations with sertraline [letter]. Mar 446–447
Marcos T see Navarro V
Marcus R see McQuade RD
Marcus SC see Olfson M
Marder SR see Miller AL
Margallo-Lana ML see Ballard CG
Margolese HC see Bhanji NH
Markson LE see Hu XH
Marmai L see Grassi L
Marom S see Hermesh H
Marriott M see Boylan KR
Marshall RD, Galea S. Science for the community: assessing mental health after 9/11. Suppl 1, 37–43
Marshall RD see Ballenger JC
Martin BC see Ganguly R
Martínez G see Parellada E
Martínez RA see Mulsant BH
Martínez-Arán A see Vieta E
Marzuk PM see Leon AC
Massana G see Navarro V
Mateos JJ see Navarro V
Matoo SK see Gupta N
Mauri M see Bulik CM
Mazure CM see Batten SV
McCall WV see Perlis ML
McClellan JM see Reimherr JP
McClintock SM see Husain MM
McConaha CW see Barbarich NC
McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. Suppl 6, 20–29
McCue RE, Waheed R, Urcuyo L. Reply to Lindenmayer J-P: Measuring efficacy of polypharmacy in schizophrenic inpatients [letter]. Aug 1148
McDermott BE see Quanbeck CD
McDonald A see Saik S
McDougle CJ see Corson AH
McElhiney MC see Rabkin JG
McElroy SL. Diagnosing and treating comorbid (complicated) bipolar disorder. Suppl 15, 35–44
McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE Jr. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. Jan 50–56
McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE Jr, Nemeroff CB. Are mood disorders and obesity related? a review for the mental health professional. May 634–651
McElroy SL, Shapira NA, Arnold LM, Keck PE Jr, Rosenthal NR, Wu S-C, Capece JA, Fazzio L, Hudson JI. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. Nov 1463–1469
McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J. 52-Week, open-label continuation study of lamotrigine in the treatment of bipolar depression. Feb 204–210
McElroy SL see Dunsieth NW Jr; Hirschfeld RMA
McEvoy JP see Lindenmayer J-P; Miller AL; Volavka J
McGarvey EL see Clayton AH
McGlashan TH see Gunderson JG
McGrath J see Leucht S
McManus FC see Ninan PT
McNamara NK see Findling RL
McNulty J see Hirschfeld RMA
McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH. Comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. Suppl 18, 47–56
McShane R see Ballard CG
Mechtcheriakov S see Hausmann A; Rettenbacher MA
Mehnert A see Nasrallah HA
Meisenzahl EM see Frodl T
Melartin TK, Rytsälä HJ, Leskelä US, Lestelä-Mielonen PS, Sokero TP, Isometsä ET. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. June 810–819
Mendelson WB see James SP
Mentschel C see Sevy S
Menza M, Vreeland B, Minsky S, Gara M, Rigassio Radler D, Sakowitz M. Managing atypical antipsychotic–associated weight gain: 12-month data on a multimodal weight control program. Apr 471–477
Mercadante MT see Hounie AG
Meyer C see John U
Michael N, Erfurth A, Arolt V. Case report of mania related to discontinuation of bupropion therapy for smoking cessation [letter]. Feb 277
Michelson D see Joliat MJ
Miguel EC see Diniz JB; Hounie AG

Milis L see Misri S
Miller AH see Asnis GM
Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B. Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Apr 500–508
Miller DD see Miller AL
Miller LS see Ganguly R
Minabe Y see Yokoshima T
Minderaa RB see Hoekstra PJ
Miner CM see Joliat MJ
Ming E see Hu XH
Minsky S see Menza M
Mintz J see Chinman M; State RC
Miodovnick H see Phrolov K
Miodownik C see Lerner V
Misawa F, Miyaji S, Fujii Y, Miyata R, Obi K, Koshiishi F, Shimada H, Fukuda M, Koizumi T. Incidence of hyperglycemia in patients treated with olanzapine [letter]. Mar 443–444
Mischoulon D see Papakostas GI
Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. Dec 1607–1618
Misri S, Reebye P, Corral M, Milis L. Use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. Sept 1236–1241
Misri S see Oberlander TF
Mitchell JE see Bulik CM
Mittal D, Jimerson NA, Neely EP, Johnson WD, Kennedy RE, Torres RA, Nasrallah HA. Risperidone in the treatment of delirium: results from a prospective open-label trial. May 662–667
Mitterlehner FO see Nickel MK
Miyaji S see Misawa F
Miyata R see Misawa F
Mletzko T see Bremner JD
Mo J see Curkendall SM
Mohmand MW, Sarles RM. Review of Geller B, DelBello MP (eds): *Bipolar Disorder in Childhood and Early Adolescence*. Aug 1151–1152
Moldofsky H see Benca RM
Moleman P see Birkenhäger TK
Möller HJ see Frodl T
Montano B. Diagnosis and treatment of ADHD in adults in primary care. Suppl 3, 18–21
Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, Josiassen RC. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. Nov 1491–1498
Montgomery SA. Review of Simon RI, Gold LH (eds): *The American Psychiatric Publishing Textbook of Forensic Psychiatry*. Nov 1580–1581
Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL, for the Venlafaxine 335 Study Group. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. Mar 328–336
Morey LC see Gunderson JG
Morgan M see Krell HV
Mori K see Yamashita H
Mori N see Yokoshima T
Morin CM. Cognitive-behavioral approaches to the treatment of insomnia. Suppl 16, 33–40
Morinobu S see Toki S; Yamashita H
Morosini P see Picardi A
Moroz G. High-potency benzodiazepines: recent clinical results. Suppl 5, 13–18
Mottard J-P see Alméras N
Mueller M see Husain MM
Mulder PG see Birkenhäger TK
Muller JE see Stein DJ
Müller MJ see Wetzel H
Mulsant BH, Gharabawi GM, Bossie CA, Mao L, Martinez RA, Tune LE, Greenspan AJ, Bastean JN, Pollock BG. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. Dec 1708–1714
Mulsant BH see Whyte EM
Murakami JL see Papakostas GI
Murphy KR, Adler LA. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. Suppl 3, 12–17
Murray RM see Howes OD
Myers JE see Bowden CL
Myin-Germeys I, Krabbendam L, Delespaul PAEG, van Os J. Sex differences in emotional reactivity to daily life stress in psychosis. June 805–809
Nagao M see Yamashita H
Nahon D see Weiser M
Nahshoni E, Weizman A, Shefet D, Pik N. Case of hyponatremia associated with escitalopram [letter]. Dec 1722
Nash JL. Review of Gabbard GO: *Long-Term Psychodynamic Psychotherapy: A Basic Text*. July 1023
Nash JL. Review of Winston A, Rosenthal RN, Pinsker H (eds): *Introduction to Supportive Psychotherapy*. Dec 1726
Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Apr 531–536. Correction, Aug 1150
Nasrallah HA see Mittal D
Navarro MA see Arranz B
Navarro V, Gastó C, Lomeña F, Mateos JJ, Portella MJ, Massana G, Bernardo M, Marcos T. Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. May 656–661
Neely EP see Mittal D
Nelson EB see Dunsieth NW Jr; McElroy SL
Nelson MW see Arnold DS
Nemeroff CB. Neurobiological consequences of childhood trauma. Suppl 1, 18–28
Nemeroff CB see Ballenger JC; Bremner JD; McElroy SL
Nestadt G see Coccaro EF
Neuse E see Diaz E
NeVeR Study Group see Wetzel H
Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. Suppl 18, 36–46
Newcomer JW see Casey DE; Kane JM
Newman S see Le Mellédo J-M
Ng Ying Kin NMK see Steiger H
Nicholas LM, Ford AL, Esposito SM, Ekstrom RD, Golden RN. Reply to Le Mellédo J-M: Effects of newer antidepressants on low-density lipoprotein cholesterol levels [letter]. July 1017–1018
Nickel C see Nickel MK
Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. Nov 1515–1519
Niedermaier N, Bohrer E, Schulte K, Schlattmann P, Heuser I. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. Dec 1619–1623
Nielsen JN, Licht RW, Fogh K. Two cases of acneiform eruption associated with lamotrigine [letter]. Dec 1720–1722
Nierenberg AA see Papakostas GI
Nihalani N see Schwartz TL
Ninan PT, Hassman HA, Glass SJ, McManus FC. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. Mar 414–420
Nizny MM. Review of Buchanan A (ed): *Care of the Mentally Disordered Offender in the Community*. June 883–884
Novick DM see Fagiolini A
Noy S see Weiser M
Nurnberg HG see Bogenschutz MP
Nutt DJ, Malizia AL. Structural and functional brain changes in posttraumatic stress disorder. Suppl 1, 11–17
Nutt DJ see Ballenger JC
Oakman J see Van Ameringen M
Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Feb 230–237
Obi K see Misawa F
O'Brien JT see Ballard CG
O'Connor K see Husain MM
Oda M see Kawashima T
O'Halloran RA see Dossenbach M
Ohayon MM. Specific characteristics of the pain/depression association in the general population. Suppl 12, 5–9
Okamoto Y see Yamashita H
O'Leary OF see Lucki I
Olfson M, Marcus SC, Wan GJ, Geissler EC. National trends in the outpatient treatment of anxiety disorders. Sept 1166–1173
Oller S see Pascual JC
Olm-Shipman CM see Evins AE
Olson D see Lamberti JS
Ombelet W see Maes M
Ono Y see Stein DJ
Oosthuizen PP see Emsley R
Oquendo MA see Grunebaum MF
Oren DA see Epperson CN
Orsini L see Russell JM

Ortiz T see Amo C
Otto MW, Smits JAJ, Reese HE. Cognitive-behavioral therapy for the treatment of anxiety disorders. Suppl 5, 34–41
Owen RR see Hudson TJ
Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. Suppl 4, 5–10
Ozguven HD see Atbasoglu EC
Ozminkowski RJ see Russell JM
Pallanti S, Hollander E, Goodman WK. Qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. Suppl 14, 6–10
Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Oct 1394–1399
Palmer BW. Review of Hay DP, Klein DT, Hay LK, Grossberg GT, Kennedy JS (eds): *Agitation in Patients With Dementia: A Practical Guide to Diagnosis and Management*. Sept 1288
Pantelis C see Addington DEN
Paoli RA see Ramacciotti CE
Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. Aug 1096–1098
Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B_{12}, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. Aug 1090–1095
Papakostas GI, Petersen TJ, Iosifescu DV, Summergrad P, Sklarsky KG, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. Apr 543–546
Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. Feb 217–221
Papakostas GI see Misra M
Parachini EA see Zanarini MC
Paradiso E see Bellino S
Parameswaran S see Ananth J
Pardo TB see Ghaemi SN
Parellada E, Baeza I, de Pablo J, Martínez G. Risperidone in the treatment of patients with delirium. Mar 348–353
Pascual JC, Oller S, Soler J, Barrachina J, Alvarez E, Pérez V. Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services [letter]. Sept 1281–1283
Pascual-Leone A see Hausmann A
Pasquini M see Picardi A
Patel MX see Taylor DM
Patria L see Bellino S
Pauls DL see Hounie AG
Pearlstein T see Simpson EB
Pearsall HR see Diaz E
Peindl KS see Epperson CN
Pendse BPG, Engström G, Träskman-Bendz L. Psychopathology of seasonal affective disorder patients in comparison with major depression patients who have attempted suicide. Mar 322–327
Perel JM see Sunder KR
Perera P see Trivedi MH
Pérez V see Pascual JC
Perkonigg A, Yonkers KA, Pfister H, Lieb R, Wittchen H-U. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. Oct 1314–1322
Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. Aug 1128–1137
Perlis RH see Hennen J
Perlmutter IR. Review of Holmes J, Bateman A (eds): *Integration in Psychotherapy: Models and Methods*. May 728
Perry EB Jr, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. Feb 238–243
Peters J see Philipsen A
Petersen T see Papakostas GI
Petersen TJ see Papakostas GI
Petrides G see Husain MM
Petty RG see Littrell KH
Pfister H see Perkonigg A
Philipsen A, Richter H, Schmahl C, Peters J, Rüsch N, Bohus M, Lieb K. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Oct 1414–1419
Phrolov K, Applebaum J, Levine J, Miodovnick H, Belmaker RH. Single-dose intravenous valproate in acute mania. Jan 68–70
Piasecki SD, Jefferson JW. Psychiatric complications of deep brain stimulation for Parkinson's disease. June 845–849
Picardi A, Morosini P, Gaetano P, Pasquini M, Biondi M. Higher levels of anger and aggressiveness in major depressive disorder than in anxiety and somatoform disorders [letter]. Mar 442–443
Pickering RP see Grant BF
Pigott TA see Trivedi MH
Pik N see Nahshoni E
Pilkonis PA see Mammen OK
Pilowsky LS see Howes OD
Pinkerton R see Clayton AH
Pipe B see Van Ameringen M
Pistorello J see Simpson EB
Pitrosky B see Lydiard RB
Pitts CD see Trivedi MH
Pjrek E, Winkler D, Heiden A, Praschak-Rieder N, Willeit M, Konstantinidis A, Stastny J, Kasper S. Seasonality of birth in seasonal affective disorder. Oct 1389–1393
Plotnicov KH see Barbarich NC
Pluijms EM see Birkenhäger TK
Pollack MH see Doyle A; Simon NM
Pollock BG see Mulsant BH
Pomerantz JM, Finkelstein SN, Berndt ER, Poret AW, Walker LE, Alber RC, Kadiyam V, Das M, Boss DT, Ebert TH. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. Mar 395–404
Pope HG Jr see Hausmann A
Poret AW see Pomerantz JM
Portella MJ see Navarro V
Posey DJ see Corson AH
Post RM, Chang KD, Findling RL, Geller B, Kowatch RA, Kutcher SP, Leverich GS. Prepubertal bipolar I disorder and bipolar disorder NOS are separable from ADHD [editorial]. July 898–902
Posternak MA see Zimmerman M
Pralea C see Lim S
Praschak-Rieder N see Pjrek E
Profenno LA see Tariot PN
Pyne JM see Hudson TJ
Quanbeck CD, Stone DC, Scott CL, McDermott BE, Altshuler LL, Frye MA. Clinical and legal correlates of inmates with bipolar disorder at time of criminal arrest. Feb 198–203
Quercioli L see Pallanti S
Quesney LF see Amo C
Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. Oct 1329–1334
Rabins PV. Review of Shulman KI, Feinstein A: *Quick Cognitive Screening for Clinicians: Mini Mental, Clock Drawing, and Other Brief Tests*. Nov 1581
Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ. Modafinil treatment for fatigue in HIV+ patients: a pilot study. Dec 1688–1695
Rabkin R see Rabkin JG
Raby WN, Coomaraswamy S. Gabapentin reduces cocaine use among addicts from a community clinic sample. Jan 84–86
Rachid F, Bertschy G, Bondolfi G, Aubry J-M. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. Nov 1537–1545
Rack MJ. Review of Reite M, Ruddy J, Nagel K: *Concise Guide to Evaluation and Management of Sleep Disorders, 3rd ed.* Mar 449–450
Rack MJ, Baran AS, Richert AC, Roffwarg HP. Cardiopulmonary complications of ergot-derivative dopamine agonists [letter with reply]. Oct 1429–1430
Raison CL see Asnis GM
Ramacciotti CE, Paoli RA, Catena M, Ciapparelli A, Dell'Osso L, Schulte F, Garfinkel PE. Schizophrenia and binge-eating disorders [letter]. July 1016–1017
Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. Dec 1642–1653
Ramirez A see Baca-Garcia E

Ramírez N see Arranz B
Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. Jan 44–49
Rasetti R see Bellino S
Rasmussen K see Husain MM
Read LL see Richardson MA
Reebye P see Misri S
Reed L see Bremner JD
Reed M see Hirschfeld RMA
Reed ML see Calabrese JR
Reese HE see Otto MW
Regan WM. Review of Mann SC, Caroff SN, Keck PE Jr, Lazarus A: *Neuroleptic Malignant Syndrome and Related Conditions, 2nd ed.* May 728–729
Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. Preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Dec 1601–1606
Reimherr JP, McClellan JM. Diagnostic challenges in children and adolescents with psychotic disorders. Suppl 6, 5–11
Reinstein MJ see Glazer WM
Reiser M see Frodl T
Renes J-W see Birkenhäger TK
Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, Fleischhacker WW. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. Sept 1211–1218
Rettenbacher MA, Hummer M, Fleischhacker WW, Lechleitner M. Transient hyperproinsulinemia during treatment with clozapine and amisulpride [letter]. June 878–879
Rettenbacher MA, Mechtcheriakov S, Bergant A, Brugger A, Fleischhacker WW. Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia [letter]. Feb 275–277
Reynolds CF III see Whyte EM
Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. Jan 92–96
Richert AC see Rack MJ
Richter H see Philipsen A
Rigassio Radler D see Menza M
Riggs W see Oberlander TF
Righi R see Grassi L
Rigotti NA see Evins AE
Roby D see Dunsieth NW Jr
Rocca P see Bellino S
Rodrigues-Scott M see Henderson DC
Roffwarg HP see Rack MJ
Romano SJ see Addington DEN
Rosário-Campos MC see Diniz JB; Hounie AG
Rosel P see Arranz B
Rosen K see Simpson EB
Rosen RM see Bystritsky A
Rosenbaum JF. Development of clonazepam as a psychotropic: the Massachusetts General Hospital experience. Suppl 5, 3–6
Rosenbaum JF see Papakostas GI
Rosenheck R see Sernyak MJ
Rosenthal NR see McElroy SL
Rosse RB see Arnold DS
Roth LS. Acetaminophen preferable to ibuprofen for pretreatment of electroconvulsive therapy–induced headache [letter]. May 726
Roth T. Characteristics and determinants of normal sleep. Suppl 16, 8–11
Roth T. Measuring treatment efficacy in insomnia. Suppl 8, 8–12
Roth T see Krystal AD
Rother WK see Nickel MK
Rotondo A see Bulik CM
Rouillon F see Esposito D; Slama F
Rousseva A see Slama F
Roussin J see Steiger H
Roy M-A see Alméras N
Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. Suppl 13, 20–26
Ruan WJ see Grant BF
Rucci P see Fagiolini A
Rudolph RL see Montgomery SA
Ruggiero L see Lepola U
Ruiz P. Review of Westermeyer JJ, Weiss RD, Ziedonis DM (eds): *Integrated Treatment for Mood and Substance Use Disorder.* Aug 1151
Rummans T see Husain MM
Rumpf H-J see John U
Rupp CI see Hausmann A
Rurak D see Oberlander TF
Rüsch N see Philipsen A
Rush AJ see Husain MM; Miller AL; Russell JM
Russell JM, Hawkins K, Ozminkowski RJ, Orsini L, Crown WH, Kennedy S, Finkelstein S, Berndt E, Rush AJ. Cost consequences of treatment-resistant depression. Mar 341–347
Russell JM see Gelenberg AJ
Ryan JL see Papakostas GI
Ryan ND see Yorbik O
Ryback RS. Naltrexone in the treatment of adolescent sexual offenders. July 982–986
Rytsälä HJ see Melartin TK
Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, Lindeman S. Hyperlipidemia in persons using antipsychotic medication: a general population–based birth cohort study. Apr 547–550
Sachs G see Hennen J
Sacks FM. Metabolic syndrome: epidemiology and consequences. Suppl 18, 3–12
Saeed SA see Miller AL
Saik S, Kraus JE, McDonald A, Mann SG, Sheitman BB. Neurosyphilis in newly admitted psychiatric patients: three case reports. July 919–921
Saiz-Ruiz J see Baca-Garcia E
Saka MC see Atbasoglu EC
Sakowitz M see Menza M
Salerian AJ. Successful treatment of sexual dysfunction with dronabinol: a case report [letter]. Aug 1146–1147
Salomon RM. Review of Kirshner HS: *Behavioral Neurology: Practical Science of Mind and Brain, 2nd ed.* Mar 448
Salomon RM. Review of Panksepp J: *Textbook of Biological Psychiatry.* Aug 1152–1153
Salvi V see Maina G
Salzman C. Review of Mellow AM (ed): *Geriatric Psychiatry.* Sept 1289
Sambamoorthi U see Walkup JT
Samuels JF see Coccaro EF
Samuels S, Fang M. Olanzapine may cause delirium in geriatric patients [letter]. Apr 582–583
San L see Arranz B
Sanacora G see Perry EB Jr
Sanchez JM see Arranz B
Sánchez-Moreno J see Vieta E
Sanislow CA see Gunderson JG
Sansone RA, Sears CD. Successful use of meclizine in panic disorder [letter]. Sept 1285–1286
Sarles RM see Mohmand MW
Sasaki Y, Kusumi I, Koyama T. Case of tardive dystonia successfully managed with quetiapine [letter]. Apr 583–584
Saxena S see Bystritsky A
Schäfer A see Kraus MR
Schatzberg AF. Employing pharmacologic treatment of bipolar disorder to greatest effect. Suppl 15, 15–20
Schatzberg AF. Introduction. Pharmacologic treatments of major depression: are two mechanisms really better than one? Suppl 4, 3–4
Schatzberg AF. Introduction: the relationship of chronic pain and depression. Suppl 12, 3–4
Schell T see Chinman M
Scheurich A see Wetzel H
Schläfke D see Wetzel H
Schlattmann P see Niedermaier N
Schmahl C see Philipsen A
Schmidt CA see Coccaro EF
Schmidt ME see Joliat MJ
Schneider BS see Koller EA
Schnitt J see Lim S
Schoenecker CJ see Chaudron LH
Schooler NR see Miller AL; Sevy S
Schorr C see Frodl T
Schronen J see Emsley R
Schulte F see Ramacciotti CE
Schulte K see Niedermaier N
Schwab JJ. Review of Winston A: *Handbook of Integrated Short-Term Psychotherapy.* Jan 136–137
Schwartz JRL. Pharmacologic management of daytime sleepiness. Suppl 16, 46–49
Schwartz TL, Azhar N, Cole K, Hopkins G, Nihalani N, Simionescu M, Husain J, Jones N. Open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. Sept 1223–1227
Schwenk TL see Culpepper L
Scott CL see Quanbeck CD
Scott JA see Fagiolini A
Seamonds B see Montgomery J
Sears CD see Sansone RA
Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Feb 244–248
Segev S see Lepkifker E
Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. Dec 1597–1600
Sernyak MJ see Casey DE

Sevy S, Visweswaraiah H, Mentschel C, Leucht S, Schooler NR. Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. June 756–765
Shaheen MO see Dossenbach M
Shalev AY, Tuval-Mashiach R, Hadar H. Posttraumatic stress disorder as a result of mass trauma. Suppl 1, 4–10
Shalev AY see Ballenger JC
Shapira NA see McElroy SL
Shavitt RG see Diniz JB; Hounie AG
Shea MT see Gunderson JG
Shefet D see Nahshoni E
Sheitman B see Lindenmayer J-P; Saik S; Volavka J
Sheldon-Keller A see Clayton AH
Shelef A see Aviv A
Shelton CI. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? Suppl 17, 29–33
Shelton RC. Dual-action hypothesis: does pharmacology matter? Suppl 17, 5–10
Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. Dec 1715–1719
Shelton RC see Gelenberg AJ
Shen WW see Lu M-L
Shen YC see Zhang XY
Shiloh R see Hermesh H
Shimada H see Misawa F
Shon SP see Miller AL
Siddiq S see Bremner JD
Sidhom T see Ananth J
Siegel JM. Neurotransmitters of sleep. Suppl 16, 4–7
Silk KR see Zanarini MC
Silverstone PH. Qualitative review of SNRIs in anxiety. Suppl 17, 19–28
Sim K, Chong PN, Chan YK, Soon WSW. Severe acute respiratory syndrome–related psychiatric and posttraumatic morbidities and coping responses in medical staff within a primary health care setting in Singapore. Aug 1120–1127
Simionescu M see Schwartz TL
Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, Link N, Pollack MH. Open-label study of levetiracetam for the treatment of social anxiety disorder. Sept 1219–1222
Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, Pearlstein T. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Mar 379–385
Singer P see Wetzel H
Sittinger H see Wetzel H
Sklarsky KG see Papakostas GI
Skodol AE see Gunderson JG
Slama F, Bellivier F, Henry C, Rousseva A, Etain B, Rouillon F, Leboyer M. Bipolar patients with suicidal behavior: toward the identification of a clinical subgroup. Aug 1035–1039
Slattery MJ, Dubbert BK, Allen AJ, Leonard HL, Swedo SE, Gourley MF. Prevalence of obsessive-compulsive disorder in patients with systemic lupus erythematosus. Mar 301–306
Small AM see Richardson MA
Smeraldi E see Cavallaro R
Smit R see Emsley R
Smith G see Husain MM
Smits JAJ see Otto MW
Sokero TP see Melartin TK
Soler J see Pascual JC
Solomon DA see Zimmerman M
Solomons K see Lam RW
Sonnenberg JG see Glazer WM
Soon WSW see Sim K
Soreni N, Weizman A, Weiss M. Beneficial effects of gonadotropin-releasing hormone analogue treatment on positive and negative symptoms of schizophrenia: a case report [letter]. July 1020–1021
Sorter MT see McConville BJ
Soutullo CA see Dunsieth NW Jr
SPD417 Study Group see Ketter TA; Weisler RH
Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities see Aman MG
Spencer TJ. ADHD treatment across the life cycle. Suppl 3, 22–26
Spigset O see Berle JØ
Spoelstra JA, Stolk RP, Cohen D, Klungel OH, Erkens JA, Leufkens HGM, Grobbee DE. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. May 674–678
Stahl SM. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as $\alpha_2\delta$ ligands at voltage-gated calcium channels [Brainstorms]. May 596–597
Stahl SM. Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA [Brainstorms]. Mar 291–292
Stahl SM. Anticonvulsants as anxiolytics, part 2: pregabalin and gabapentin as $\alpha_2\delta$ ligands at voltage-gated calcium channels [Brainstorms]. Apr 460–461
Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels [Brainstorms]. June 738–739
Stahl SM. Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence? [Brainstorms] Oct 1298–1299
Stahl SM. Mechanism of action of $\alpha_2\delta$ ligands: voltage sensitive calcium channel (VSCC) modulators [Brainstorms]. Aug 1033–1034
Stahl SM. Mechanism of action of voltage sensitive sodium channel modulators [Brainstorms]. July 894–895
Stahl SM. Preemptive analgesia: is pain less costly when you pre-pay for it? [Brainstorms] Dec 1591–1592
Stahl SM. Prophylactic antipsychotics: do they keep you from catching schizophrenia? [Brainstorms] Nov 1445–1446
Stahl SM. Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? [Brainstorms] Feb 149–150
Stahl SM. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator [Brainstorms]. Sept 1162–1163
Stahl SM. Symptoms and circuits, pt 3: schizophrenia [Brainstorms]. Jan 8–9
Stahl SM see Gelenberg AJ; Shelton RC
Stanculescu C see Reich DB
Stang MR see Curkendall SM
Stastny J see Pjrek E
State RC, Frye MA, Altshuler LL, Strober M, DeAntonio M, Hwang S, Mintz J. Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. Aug 1057–1063
Statsenko N see Lerner V
Steen VM see Berle JØ
Steenhuis M-P see Hoekstra PJ
Steiger H, Gauvin L, Israël M, Ng Ying Kin NMK, Young SN, Roussin J. Serotonin function, personality-trait variations, and childhood abuse in women with bulimia-spectrum eating disorders. June 830–837
Stein DJ, Ono Y, Tajima O, Muller JE. Social anxiety disorder spectrum. Suppl 14, 27–33
Stein MB. Public health perspectives on generalized anxiety disorder. Suppl 13, 3–7
Stein MB see Seedat S
Sterck R see Damsa C
Stewart DE see Dennis C-LE
Stigler KA see Corson AH
Stinson FS see Grant BF
St. Lambert J see Lepola U
Stock E see McQuade RD
Stolk RP see Spoelstra JA
Stone DC see Quanbeck CD
Stout RL see Gunderson JG
Streim J see Alexopoulos GS
Strober M see Bulik CM; State RC
Stroup S see Miller AL
Sudak HS. Review of Morrison J, Muñoz RA: *Boarding Time: The Psychiatry Candidate's New Guide to Part II of the ABPN Examination, 3rd ed.* July 1022
Sullivan G see Hudson TJ
Sullivan MC see Diaz E
Summergrad P see Papakostas GI
Sunbol MM see Dossenbach M
Sunder KR, Wisner KL, Hanusa BH, Perel JM. Postpartum depression recurrence versus discontinuation syndrome: observations from a randomized controlled trial. Sept 1266–1268
Suppes T see Dennehy EB; Majeres KD; McElroy SL
Sutor B. Rose by any other name [letter]. 584
Sverdlik A see Lepkifker E
Swann A see Ballard CG
Swann AC, Daniel DG, Kochan LD, Wozniak PJ, Calabrese JR. Psychosis in mania: specificity of its role in severity and treatment response. June 825–829
Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. Dec 1666–1673

Swartz MS see Swanson JW
Swedo SE see Slattery MJ
Szegedi A see Wetzel H
Tajima O see Stein DJ
Takei N see Yokoshima T
Takeshita J. Use of propofol for alcohol withdrawal delirium: a case report [letter]. Jan 134–135
Tani K see Yokoshima T
Tardiff K see Leon AC
Tarin-Godoy B see Miller AL
Tariot PN. Introduction: clinical effectiveness of atypical antipsychotics in dementia. Suppl 11, 3–4
Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. Suppl 11, 11–15
Taylor DM. Reply to Duggal HS: Comments on cost analysis of risperidone versus olanzapine [letter]. June 879–880
Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. Aug 1076–1083
Taylor DM see Werneke U
Taylor P Jr see Dunsieth NW Jr
Teres JJ see Leon AC
Terman JS see Epperson CN
Terman M see Epperson CN
Thapa P see Hudson TJ
Thase ME. Introduction. The dual-action debate: does pharmacology matter? Suppl 17, 3–4
Thase ME see Gelenberg AJ
Thienhaus OJ. Review of Miller MD, Reynolds CF: *Living Longer Depression Free: A Family Guide to Recognizing, Treating, and Preventing Depression in Later Life*. Jan 137
Thomas A see Ballard CG
Thornton L see Bulik CM
Thrush CR see Hudson TJ
Todd L see Gelenberg AJ
Tohen M see Hennen J; Vieta E
Toki S, Morinobu S, Yoshino A, Yamawaki S. Case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics [letter]. Nov 1576–1577
Tolin DF, Maltby N, Diefenbach GJ, Hannan SE, Worhunsky P. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list–controlled open trial. July 922–931
Torres RA see Mittal D
Torres S see Astruc B
Trapp NJ see Joliat MJ
Träskman-Bendz L see Pendse BPG
Trevino JJ. Review of the American Psychiatric Association: *Quality Indicators: Defining and Measuring Quality in Psychiatric Care for Adults and Children (Report of the APA Task Force on Quality Indicators and Report of the APA Task Force on Quality Indicators for Children)*. Apr 585
Trevino JJ. Review of Johnson B, Ruiz P, Galanter M (eds): *Handbook of Clinical Alcoholism Treatment*. Dec 1726–1727
Tritt K see Nickel MK
Trivedi MH, Pigott TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. Oct 1356–1364
Tsai S-J see Kao C-L
Tsuyuki R see Le Mellédo J-M
Tune LE see Mulsant BH
Turkoz I see Currier GW
Turner HJ see Emsley R
Tuval-Mashiach R see Shalev AY
Ueki H see Kawashima T
Urcuyo L see McCue RE
Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M. Open trial of topiramate in the treatment of generalized social phobia. Dec 1674–1678
van den Broek WW see Birkenhäger TK
van der Wee N see Denys D
Van Dorn RA see Swanson JW
van Duijn H see Koerselman F
van Duijn MAJ see Koerselman F
van Megen HJGM see Denys D
van Os J see Myin-Germeys I
Vanveggel S see McQuade RD
Vapnik T see Bystritsky A
Velligan DI see Harvey PD
Venlafaxine 335 Study Group see Montgomery SA
Ventura D see Bielski RJ
Vidailhet P see Damsa C
Vieta E, Calabrese JR, Hennen J, Colom F, Martínez-Arán A, Sánchez-Moreno J, Yatham LN, Tohen M, Baldessarini RJ. Comparison of rapid-cycling and non–rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. Oct 1420–1428
Villeneuve J see Alméras N
Visweswaraiah H see Sevy S
Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Jan 57–61
Volavka J see Lindenmayer J-P
Vornik LA see Hirschfeld RMA
Vreeland B see Menza M
Wagner A see Roy-Byrne PP
Wagner KD. Diagnosis and treatment of bipolar disorder in children and adolescents. Suppl 15, 30–34
Wagner KD see Hirschfeld RMA
Waheed R see McCue RE
Walch T see Hausmann A
Walker LE see Pomerantz JM
Walkup JT, Sambamoorthi U, Crystal S. Use of newer antiretroviral treatments among HIV-infected Medicaid beneficiaries with serious mental illness. Sept 1180–1189
Walpoth M see Hausmann A
Walsh JK. Clinical and socioeconomic correlates of insomnia. Suppl 8, 13–19
Walsh JK. Pharmacologic management of insomnia. Suppl 16, 41–45
Walsh JK see Perlis ML
Wan GJ see Olfson M
Warnock JK see Clayton AH
Watkin JG see Fava M; Wohlreich MM
Watts T see Reich DB
Weber J see Koller EA
Weinmann S, Janssen B, Gaebel W. Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. Aug 1099–1105
Weinstein D. Review of Mueser KT, Noordsy DL, Drake RE, Fox L: *Integrated Treatment for Dual Disorders: A Guide to Effective Practice*. Dec 1727
Weiser M, Knobler H, Lubin G, Nahon D, Kravitz E, Caspi A, Noy S, Knobler HY, Davidson M. Body mass index and future schizophrenia in Israeli male adolescents. Nov 1546–1549
Weisler RH, Kalali AH, Ketter TA, and the SPD417 Study Group. Multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. Apr 478–484
Weisler RH see Ketter TA
Weiss EM see Hausmann A; Rettenbacher MA
Weiss JR see Weiss MD
Weiss L see Glick ID
Weiss M see Soreni N
Weiss MD, Weiss JR. Guide to the treatment of adults with ADHD. Suppl 3, 27–37
Weiss NT, Jones L, Chamberlain JC. Possible case of venlafaxine-induced Stevens-Johnson syndrome [letter]. Oct 1431–1433
Weissman MM see Hirschfeld RMA
Weizman A see Aviv A; Hermesh H; Nahshoni E; Soreni N
Welge JA see Dunsieth NW Jr
Welter S see Bremner JD
Werneke U, Horn O, Taylor DM. How effective is St. John's wort? the evidence revisited. May 611–617
Westenberg HGM, Liebowitz MR. Overview of panic and social anxiety disorders. Suppl 14, 22–26
Westenberg HGM see Denys D
Wetzel H, Szegedi A, Scheurich A, Lörch B, Singer P, Schläfke D, Sittinger H, Wobrock T, Müller MJ, Anghelescu I, Hautzinger M, for the NeVeR Study Group. Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. Oct 1406–1413
White C see Lydiard RB
White R see Goodwin GM
Whyte EM, Basinski J, Farhi P, Dew MA, Begley A, Mulsant BH, and Reynolds CF III. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. Dec 1634–1641
Wiener K see Lamberti JS
Wilens TE, Dodson W. Clinical perspective of attention-deficit/hyperactivity disorder into adulthood. Oct 1301–1313
Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. Suppl 3, 38–45
Williams C see Bremner JD
Williamson DE see Yorbik O
Willeit M see Pjrek E

Willems MAM see Koerselman F
Winkler D see Pjrek E
Winterbottom E see Montgomery J
Winternitz S see Reich DB
Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. Suppl 18, 13–26
Wisner KL. Sex and psychiatry in the next 5 years [editorial]. Apr 462–463
Wisner KL see Epperson CN; Sunder KR
Wittchen H-U see Bittner A; Perkonigg A
Wobrock T see Wetzel H
Wohlreich MM, Watkin JG, Gonzales JS. Duloxetine's role in the treatment of depression and associated painful physical symptoms [letter]. July 1018–1019
Wohlreich MM see Fava M
Wolf J see Anghelescu I
Wong E see Lee E
Woods SW see Diaz E
Woodside DB see Bulik CM
Woofter C see Lu BY
Worhunsky P see Tolin DF
Worthington JJ see Simon NM
Wozniak PJ see Swann AC
Wu GY see Zhang XY
Wu S-C see McElroy SL
Xie H see Clark RE
Xie Y see Bowden CL; Clark RE
Yamada S see Kawashima T
Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. Nov 1525–1530
Yamawaki S see Toki S; Yamashita H
Yang Y-J see Kao C-L
Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. Suppl 10, 28–35
Yatham LN see Lam RW; Vieta E
Yehuda R. Risk and resilience in posttraumatic stress disorder. Suppl 1, 29–36
Yehuda R see Ballenger JC
Yen S see Gunderson JG; Simpson EB
Yokoshima T, Takei N, Tani K, Kawai M, Minabe Y, Mori N. Two cases of perospirone-induced mania in schizophrenia [letter]. Jan 135
Yonkers KA see Perkonigg A
Yorbik O, Birmaher B, Axelson D, Williamson DE, Ryan ND. Clinical characteristics of depressive symptoms in children and adolescents with major depressive disorder. Dec 1654–1659
Yoshino A see Toki S
Young AS see Chinman M
Young CL see Taylor DM
Young D see Zimmerman M
Young FK see Glick ID
Young LT see Boylan KR
Young SN see Steiger H
Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. Suppl 16, 12–16
Zahlsen K see Berle JØ
Zajecka JM, Albano D. SNRIs in the management of acute major depressive disorder. Suppl 17, 11–18
Zamarian L see Marcon G
Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. Jan 28–36
Zanarini MC, Frankenburg FR, Parachini EA. Preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. July 903–907
Zanarini MC see Frankenburg FR; Gunderson JG
Zaninelli R see Glick ID
Zarate CA see Gould TD; McElroy SL
Zetzsche T see Frodl T
Zhang PY see Zhang XY
Zhang S see Joliat MJ
Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. July 940–947
Zhao W see Husain MM
Zheng H see Rapaport MH
Zhou DF see Zhang XY
Zimmerman M, Chelminski I, Young D. On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. Oct 1400–1405
Zimmerman M, Posternak MA, Chelminski I. Defining remission on the Montgomery-Asberg Depression Rating Scale. Feb 163–168
Zimmerman M, Posternak MA, Chelminski I, Solomon DA. Using questionnaires to screen for psychiatric disorders: a comment on a study of screening for bipolar disorder in the community [commentary]. May 605–610
Ziv R see Lepkifker E
Zohar J, Kennedy JL, Hollander E, Koran LM. Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. Suppl 14, 18–21
Zohar J see Denys D; Hollander E

Online Manuscript Submission and **Peer Review**

Our user-friendly system offers **security, convenience, and speed**

Physicians Postgraduate Press, Inc.

@ www.psychiatrist.com/submissions